The regulation of alternative splicing associated with Myotonic Dystrophy by Warf, Michael Bryan
THE REGULATION OF ALTERNATIVE SPLICING ASSOCIATED WITH
MYOTONIC DYSTROPHY
by
MICHAEL BRYAN WARP
A DISSERTATION
Presented to the Department of Chemistry
And the Graduate School of the University of Oregon
in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy
September 2009
11
University of Oregon Graduate School
Confirmation of Approval and Acceptance of Dissertation prepared by:
Michael Warf
Title:
"The regulation of alternative splicing associated with Myotonic Dystrophy"
This dissertation has been accepted and approved in partial fulfillment of the requirements for
the Doctor of Philosophy degree in the Department of Chemistry by:
Kenneth Prehoda, Chairperson, Chemistry
1. Andrew Berglund, Advisor, Chemistry
Victoria DeRose, Member, Chemistry
Peter von Hippel, Member, Chemistry
Alice Barkan, Outside Member, Biology
and Richard Linton, Vice President for Research and Graduate Studies/Dean of the Graduate
School for the University of Oregon.
September 5, 2009
Original approval signatures are on file with the Graduate School and the University of Oregon
Libraries.
iii
An Abstract of the Dissertation of
Michael Bryan Warf
in the Department of Chemistry
for the degree of
to be taken
Doctor of Philosophy
September 2009
Title: THE REGULATION OF ALTERNATIVE SPLICING ASSOCIATED WITH
MYOTONIC DYSTROPHY
Approved: _~ ~ _
Dr. 1. Andrew Berglund
Myotonic Dystrophy (DM) is a genetic disorder with multisystemic symptoms
that is caused by expression (as RNA) of expanded repeats of CTG or CCTG in the
genome. It is hypothesized that the protein MBNLI (Musde12lind-like-l) is sequestered
to the expanded CUG or CCUG RNAs. MBNL1 regulates the alternative splicing ofa
variety ofpre-mRNAs and its mis-localization results in mis-splicing of a subset of pre-
mRNAs that are linked to the symptoms found in DM patients.
I initially demonstrated that MBNLI can bind short structured CUG and CCUG
repeats with high affinity and specificity in vitro. Next, I was able to determine and
articulate the first structure of a binding site of MBNL1 in an endogenous pre-mRNA that
IV
it regulates. I found that MBNL1 binds a stem-loop in the cardiac troponin T (cTNT) pre-
mRNA. The stem-loop contains two mismatches and resembles both CUG and CCUG
repeats. I determined that MBNL I regulated exon 5 by directly competing with the
essential splicing factor U2AF65 for binding upstream of exon 5. When U2AF65 is
prevented from binding, factors in the spliceosome can no longer be recruited and the
following exon is skipped. Furthermore, I found that MBNL 1 and U2AF65 compete by
binding mutually exclusive RNA structures.
I also characterized a potential therapeutic approach for DM. Current data suggest
that if MBNL 1 is released from sequestration, disease symptoms may be alleviated.
Using a targeted screen of small molecules known to bind structured nucleic acids, I
identified the small molecule pentamidine as a compound that disrupted MBNLI binding
to CUG repeats in vitro. I showed in cell culture that pentamidine was able to reverse the
mis-splicing of two pre-mRNAs affected in DM. Pentamidine also significantly reduced
the formation of RNA foci in tissue culture cells, which are characteristic ofDM.
MBNL I was released from the foci in the treated cells. Furthermore, pentamidine
partially rescued splicing defects of two pre-mRNAs in mice expressing expanded CUG
repeats.
This dissertation includes three previously published co-authored publications.
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1CHAPTER I
INTRODUCTION
Constitutive pre-mRNA splicing
The canonical model for gene expression in cells is for DNA to be transcribed into RNA,
and the RNA used as a template for translation into a protein. However, in eukaryotic cells RNA
must undergo significant processing to mature into a message that can be used for translation.
One key processing event is splicing.
During the process of splicing, non-coding introns are removed from pre-mRNAs, and
coding exons are ligated together. The spliceosome is the machinery that recognizes and splices
out introns (see Figure I fora model of the steps of spliceosomal recruitment, and for a review
see (1,2)). The spliceosome is composed of many different proteins and protein-RNA complexes,
that are used to recognize different sequence elements in the pre-mRNA, as well as interact with
other parts of the spliceosome. It is thought that certain proteins and protein-RNA complexes
recognize the intron in a sequential manner and discreet complexes form on the pre-mRNA
during these different stages. The major spliceosome, which splices the majority ofintrons, has 5
major protein-RNA complexes, with a host of other protein factors. These large protein-RNA
complexes are called snRNPs (small nuclear ribonuclear proteins), and are labeled Ul, U2, U4,
US and U6 (3, 4).
Early complex, or E complex (5), is first to form on the pre-mRNA, and is generally
defined as the point in which the UI snRNP has been recruited to the 5' splice site and the RNA
portion of the Ul snRNP base-pairs with the 5' splice site; at the 3' splice site only the
U2AF65/35 heterodimer and SFI have been recruited (6). This is an ATP independent step,
where many key nucleotide sequences in the intron are recognized for the first time, such as the
3' and 5' splice sites and the branch-point adenosine. Following E complex, U2AF65 recruits the
U2 snRNP to the branch-point sequence to form A complex, which is an ATP dependent process
(7, 8). The RNA portion of the U2 snRNP base-pairs with the branch-point sequence, with the
25' splice site Branch-point 3' splice site
" Adenosine.
~---A~
Ccomplex
mRNA
Figure 1. Model ofspliceosomal assembly. Exons are represented by boxes, the intron by a line.
The branch-point adenosine and 5' and 3' splice sites are noted. Spliceosomal assembly
is seen to be a sequential process, at least in vitro, as different proteins and protein-RNA
complexes (known as snRNPs, or small nuclear ribonuclear proteins) load onto the pre-
mRNA. For future reference note that, in E complex, the proteins SFI, U2AF65 and
U2AF35 recognize sequences in the 3' end of the intron and help recruit the U2 snRNP to
the intron in A complex.
branch-point base (nearly always an adenosine) excluded from base-pairing and flipped out. Next,
the U41U5/U6 tri-snRNP is recruited to the 5' splice site to form B complex (9, 10). Finally,
structural rearrangements in the snRNPs and the dissociation ofU4 lead to the catalytic C
complex, where the intron is spliced out and the exons ligated together (9, 10).
There are many key sequences within the pre-mRNA that help define the 3' and 5' splice
sites, as well as the location of the branch-point. Currently, four canonical sequences are
considered to be important for splicing (Figure 2), with a host of other auxiliary sequences in
adjacent regions of the pre-mRNA also being important for splicing in certain pre-mRNAs (11).
Both the 5' and 3' splice site have strong consensus sequences and do not vary often. The 5'
splice site consensus sequence AGGTRAG base-pairs with part of the RNA portion ofthe UI
3snRNP, while the 3' splice site YAG is bound by the protein factor U2AF35 (11). The branch-
point sequence, which is bound by the RNA portion of the U2 snRNP, is not well conserved in
higher eukaryotes. The "ideal" branch-point for base pairing with the U2 snRNP is UACUAAC,
but in human, the consensus branch-point is the more degenerate sequence CURAY (11). The
branch-point is ideally located within 50 bases of the 3' splice site, but there are many exceptions
to this in higher eukaryotes. Finally, the poly-pyrimidine tract (py-tract), is the least conserved of
all the sequences. It preferably consists of a run of at least 8 pyrimidine residues, and is located
somewhere between the branch-point and the 3' splice site. The py-tract serves as a binding site
for the protein U2AF65, and aids in E complex formation, when U2AF65 first binds the pre-
mRNA (12, 13). Only ~40% of introns have ideal py-tracts, suggesting that this is not always a
required sequence for splicing.
exon
intron
I
branch point
sequence (BPS)
I
poly-pyrimidine
(Py) tract
exon
Figure 2. Canonical sequence elements within an intron. The four main sequence elements
within an intron are noted. The 5' and 3' splice sites have relatively good consensus
sequences, while the branch-point sequence andpy-tract are much more degenerate in
their sequence and location. Adapted from (11).
Alternative pre-mRNA splicing
During splicing, many different mRNAs can be made from a single pre-mRNA,
depending on which exons are included in the final mRNA. This is called alternative splicing (for
review see (14)). A current study of 10,000 human genes found that 74% were alternatively
spliced (15), while other studies have found that potentially 95% of genes are alternatively
spliced, to some degree (16). There are many different ways in which a pre-mRNA can be
alternatively spliced (Figure 3). The most common type of alternative splicing is when a single
exon is either chosen to be included or excluded, and is referred to as a cassette exon (Figure 3A).
Another common type is for an alternate 3' or 5' splice site to be chosen and is referred to as a 3'
4or 5' isoform, depending on which splice site is alternatively spliced (Figure 3B-C). The
alternative splice site that is chosen can be either further into the intron, or the exon. Finally, a
third common form of alternative splicing is intron retention, when an intron is simply not spliced
at all (Figure 3D). This can often introduce a premature termination codon into the mRNA,
leading to mRNA degradation through nonsense-mediated decay.
In many cases, sequences other than the four canonical sequences have been shown to
affect alternative splicing. In some cases, specific proteins which bind these sequences.
Sequences that increase splicing efficiency of a certain splice variant are known as enhancers, and
more specifically as an Intronic Splicing Enhancer (ISE) if the sequence is in the intron, or
Exonic Splicing Enhancers (ESE) if it is in the exon. Conversely, sequences that inhibit splicing
efficiency of a certain splice variant are known as splicing suppressors. Ifthe sequence is in the
intron it is called an Intronic Splicing Suppressor (ISS), and an Exonic Splicing Suppressor (ESS)
if it is in the exon (for review on auxiliary splicing signals see (17».
It is assumed that these sequences are bound by alternative splicing factors to regulate
which splice variant is made. In many cases, these alternative splicing factors interact with the
pre-mRNA during the initial recognition and definition of the intron. At these early stages of
intron recognition, these alternative splicing factors can aid or inhibit in the recruitment of
spliceosomal proteins in their binding of their cognate sequence elements within the pre-mRNA.
Myotonic Dystrophy (DM) and alternative splicing
Many diseases are known to arise from the mis-regulation of alternative splicing (18).
Some of these diseases occur because mutations alter binding sites for essential spliceosomal
proteins, which leads to mis-splicing events and therefore functional changes in proteins (19).
One of the first documented examples is from the aberrant splicing of the ~-globin pre-mRNA. In
patients with the disease ~+ thalassemia, mutations were found that activated an abnormal 3'
splice site in the pre-mRNA, which changes the ~-globin protein and leads to anemia and
sometimes death (20).
Splicing may also be mis-regulated due to changes in the function of alternative splicing
factors. One of the best studied models of such a disease is Myotonic Dystrophy (DM, for a
review see (21,22». In this complicated disease, there are a range of seemingly unrelated
symptoms, such as myotonia, myopathy, cardiac arrhythmia, insulin resistance and cataracts.
Many heart defects are also seen and are generally the most lethal symptom. This disease is
(A) Cassette exon
-I 1···.r"~. .·I/":3·'>~
(B) 5' Isoform
-l11213~
5
(C) 3' Isoform
~ 11\213:;~
(0) Intron Retention
~.'1··1· .. ·.•• 2"1 ••.3···· .. ~
Figure 3. Common forms ofalternative splicing. (A) Cassette exon splicing is where a single
exon is either included or excluded. This is the most common form of alternative
splicing. (B-C) 5' or 3' isoform is another relatively common form of alternative splicing
where another splice site nearby is chosen. Note that this new splice site may be further
into the intron as well, though it is depicted as further into the exon. (D) Intron retention
is a form of alternative splicing where the intron is not spliced out at all.
hypothesized to occur mainly through the mis-localization of the alternative splicing factor
Muscleblind-like-l (MBNLl) (see Figure 4 for model of DM). MBNLl is mis-localized due to
the expression of aberrant CTG or CCTG repeat expansions that, on the RNA level (as CUG and
CCUG repeats), form stable stem-loop structures. MBNLl binds these stem-loops and is
sequestered from its normal role of regulating alternative splicing (23). The pre-mRNAs that
MBNLl regulates are subsequently mis-spliced, which is hypothesized to lead to subsequent
disease symptoms. As dozens ofpre-mRNAs are known to be mis-spliced in DM, the
sequestration of MBNLl may have a substantial impact of DM patients. Presently, two MBNLl
regulated mis-splicing events have been strongly correlate to certain symptoms of DM. Mis-
splicing of the chloride channel pre-mRNA is thought to give rise to myotonia (the inability to
relax a muscle) (24), and the mis-splicing of the insulin receptor pre-mRNA may lead to insulin
resistance (25). While other splicing factors have been implicated in DM (such as CUG-BP (21)),
the mis-localization of MBNLl is thought to be the primary cause for mis-splicing seen in DM
(26).
6Currently a few dozen pre-mRNAs are known to be mis-spliced in DM (22, 27), though it
is likely that global studies will identify many more pre-mRNAs that are also mis-regulated. It is
unclear if MBNLl directly regulates all these mis-spliced pre-mRNAs, but MBNLl is thought to
at least directly regulated a sub-set of them. At the point when my research began, MBNLl was
only known to cross-link with one pre-mRNA target, the cardiac troponin T (cTNT) pre-mRNA.
MBNLl was seen to cross-link to an ISS directly upstream of exon 5, and cause that exon to be
excluded (28). While sequences required for MBNLl binding were determined for the cTNT pre-
mRNA, an articulated binding site for MBNLl was not determined in that pre-mRNA.
Furthermore, a mechanistic understanding of how MBNLl regulated the cTNT pre-mRNA (or
any other pre-mRNA) also remained unclear. The second chapter of my dissertation describes my
articulation of MBNLl 's binding site in the cTNT pre-mRNA, and initial studies on how MBNLl
may regulate exon 5 and contains previously co-authored published material. The third chapter
describes an in-depth study into the mechanism ofMBNLl 's regulation of exon 5. Both chapters
contain previously published co-authored material.
D.ISEAS.E..S.IA
MBNL sequestered by toxic RNA
Muscleblind
protein WRMAL..SIAIE
MBNL binds normal
RNA target
Figure 4. Model ofMyotonic Dystrophy. The current model of DM is that the toxic RNA repeats
(either CUG or CCUG) form stable stem-loop structures. These stem-loops aberrantly
bind the protein Muscleblind (MBNL), which is an alternative splicing factor. When
MBNL is sequestered, it does not bind and regulate its pre-mRNA targets, which leads to
mis-splicing and subsequent disease symptoms.
7Relevance to cardiovascular disease and heart development
The heart defects seen in DM are variable and are usually not defects in the heart muscle
itself, but with its ability to conduct the electrical signal that keeps it beating regularly. Specific
defects include atrioventricular and intraventricular conduction abnormalities, atrial fibrillation
and ventricular arrhythmias. Sudden and lethal arrhythmias sometimes necessitate pacemakers or
implantable defibrillators. Conduction defects do not always precede lethal arrhythmias, making
sudden deaths hard to prevent (29).
Determining how the alternative splicing of the cTNT pre-mRNA is regulated is likely to
be important for understanding a potential cause for the heart defects seen in DM. The troponin
protein family consists of three types oftroponin proteins and is required for muscle function (for
review see (30)). The three types oftroponin are troponin T, troponin I, and troponin C. All three
types are found in all three muscle types (fast, slow and cardiac). The three proteins form a
complex in muscle sarcomeres that binds both actomyosin (actin associated to myofibrils) and
tropomyosin. Their function is unclear, but they all seem to jointly regulate the ATPase activity
and Ca2+ sensitivity of actomyosin (31,32). Each troponin protein has a different gene for each
muscle type (fast, slow and cardiac), as well as multiple protein isoforms within each muscle
type. This leads to a complex expression pattern, where various isoforms for each troponin gene
are differentially expressed in each muscle type in a developmental fashion.
Cardiac troponin T (cTNT) is one of the three main types of muscle troponin T's. It has at
least 4 protein isoforms in humans, which are generated through alternative splicing. At least one
of the exon skipping events is developmentally controlled in human. Exon 5 is included in fetal
cardiac cells, but excluded in adult cells (33). Exon 5 of cTNT encodes a highly acidic 10 amino
acid sequence that is conserved in nearly all mammals (32). The retention of this sequence
increases Ca2+ sensitivity, increases ATPase activity, increases force development ofthe muscle
and slows relaxation of myocardial muscle (31, 32). The aberrant retention of exon 5 in adult
cardiac cells can have severe consequences for heart health, as exon 5 retention (or the analogous
exon in other organisms) has been linked to cardiomyopathy and spontaneous heart failure in
human, cat, dog, guinea pig and turkey (32).
While it is unclear how aberrant retention of this exon in adult heart cells may cause
cardiomyopathy, it is hypothesized that retention of this isoform leads to arrhythmia by
desynchronization of heart muscle contraction, which is an important factor in cardiomyopathy
(32). Conduction abnormalities and arrhythmia of the heart are arguably the most lethal symptom
8in DM, while the heart muscle itself seems to be normal (which is unanticipated in a muscular
dystrophy with heart defects) (29). As exon 5 of the cTNT pre-mRNA is drastically increased in
DM, it seems likely that the mis-splicing of this one pre-mRNA could solely account for the
specific and unusual arrhythmia heart defects in the disease. In animal models where increased
exon 5 had high retention, similar heart defects were seen when compared with DM patients (29,
31, 32). By understanding how this process is regulated, we would gain insight into one of the
largest causes of death in DM, as well as the role of alternative splicing in heart development.
The third chapter of this dissertation details my studies on how MBNLl mechanistically regulates
exon 5 exclusion by its competition with the essential splicing factor U2AF65 and contains
previously published co-authored research.
Potential therapeutic avenues for treating Myotonic Dystrophy
Understanding how MBNLl mechanistically regulates alternative splicing is a vital step
towards understanding Dm and creating a cure for the disease. Now that we have a better
understanding of the disease state and the role of MBNL I' s sequestration in causing DM, it is
possible to hypothesize how the disease may be treated. A cure for DM would be for the CTG or
CCTG expansions to be deleted from the patients genome, but this is infeasible with the current
genetic tools. Other recent therapeutic approaches for DMI have ranged from over-expression of
MBNLl, RNA interference against the CUG repeats, to targeted degradation of the mutant
DMPK transcript with an RNA ribozyme (34-37). Aside from the over-expression ofMBNLl,
another possible approach to overcoming the sequestration ofMBNLl is to identify small
molecules that specifically bind the CUG repeats to competitively release the sequestered
MBNLl. The fourth chapter of this dissertation focuses on determining if a small molecule could
compete with MBNLl for binding of CUG repeats and alleviate mis-splicing seen in various DM
model systems and contains previously published co-authored material.
9CHAPTER II
MBNLI BINDS SIMILAR RNA STRUCTURES IN THE CUG
REPEATS OF MYOTONIC DYSTROPHY AND ITS PRE-MRNA
SUBSTRATE CARDIAC TROPONIN T
Contribution note: this chapter is previously published (War! and Berglund, 2007) (84). The
other contributor, J Andrew Berglund, helped with experimental design, data analysis and
manuscript preparation.
Introduction
Myotonic Dystrophy (DM) is a genetic disorder with multisystemic symptoms that
include myotonia, cardiac arrhythmia, insulin resistance and muscular weakness. There are two
subtypes of Myotonic Dystrophy: DMI and DM2. DMI has been linked to a (CTG)n repeat
expansion in the 3' untranslated region (3' UTR) of the DMPK gene. DM2 has been linked to
(CCTG)n repeats expansion in intron I of the ZNF9 gene. The genetic mutations in each subtype
are in two unrelated genes on different chromosomes. The symptoms observed in the two
subtypes are remarkably similar, with the only molecular commonality being the repeat
expansions. The similarity in symptoms and sequence motifs as well as the fact that both repeats
are non-coding indicate a common mechanism for both subtypes.
CUG expanded repeats fold into extended stem-loop structures, with guanosines and
cytosines forming base pairs, while the uridines form mismatches (38-40). Biochemical and
structural studies have shown that extended helical regions of the stem-loops are primarily A-
form in structure and are thermodynamically stable (40,41). The CCUG repeats ofDM2 also fold
into an extended stem-loop structure. It is currently thought this stem-loop consists of two
adjacent guanosine-cytosine base pairs and two adjacent cytosine-uracil mismatches (42,43).
However, it is possible for the RNA to anneal in another structure in which single guanosine-
cytosine base pairs are interspersed with uracil-uracil and cytosine-cytosine mismatches (see
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Figure 3A for schematic) and it is unclear if one structure predominates. Thermodynamically, the
first structure is the only one that is predicted (44).
One proposed mechanism for the disease is that, upon transcription, the CUG and CCUG
repeats sequester RNA binding proteins from their normal cellular functions. It is hypothesized
that the specific sequestration of the RNA binding protein MBNLl (Muscle!2lind-like) primarily
leads to DM symptoms. Supporting this hypothesis is a model in which expression of 250 non-
coding CUG repeats causes symptoms similar to patients with DM (45). The link between
MBNLlI and DM was strengthened with a mouse knockout model, where the MBNLlI gene
was inactivated through deletion and the mice developed many key symptoms ofDM (46).
The muscleblind family of proteins was originally identified in Drosophila melanogaster
as a gene required for muscle development and eye differentiation (47). For a review of
muscleblind see (48). There are three muscleblind paralogues in human, named MBNLlI-3. Of
the three human MBNLl proteins, MBNLlI and MBNLl2 are more abundant and have been
shown to co-localize with CUG and CCUG repeats in the nucleus, forming nuclear foci in both
DMI and DM2 (23,49-55). All three muscleblind proteins are similar in sequence, and appear to
have similar functions, as they can regulate alternative splicing in tissue culture (26, 28, 56).
However, MBNLl2 has also been shown to function in RNA localization in the cytoplasm (57).
Less is known about MBNLl3, but it is possible that MBNLlI and MBNLl3 may act
antagonistically to each other when regulating gene expression that is involved in muscle
differentiation (58).
The RNA binding protein, CUG-BP also has an important role in DM pathogenesis.
CUG-BP and hnRNP H are over-expressed in the presence of expanded CUG repeats and are
involved in controlling the alternative spicing of many of the same genes regulated by MBNLl
(25, 56, 59, 60). An antagonistic relationship exists between MBNLl and CUG-BP for several
regulated exons; where one protein acts as a positive regulator while the other protein acts as a
negative regulator. However, the actual role of each protein appears to depend on the specific pre-
mRNA and splice-junction in question. For example, for the fifth exon of the cardiac troponin T
(cTNT) pre-mRNA, CUG-BP is a positive regulator of exon five inclusion while MBNLl is a
negative regulator of exon five inclusion (28, 60, 61). Conversely, for exon 11 of the insulin
receptor pre-mRNA, the roles ofCUG-BP and MBNLl have been reversed and CUG-BP is a
negative regulator while MBNLl is a positive regulator (25, 26, 56, 62).
It is currently thought that the relative levels of these two splicing factors and other
splicing factors leads to specific pre-mRNA splice patterns (63). As these two factors compete in
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their regulation of splicing, the mis-splicing seen in DM has been hypothesized to be due to both
decreased levels of MBNLl and/or increased levels of CUB-BP. Supporting both models, mice in
which MBNLl is knocked out show DM symptoms, as do mice in which CUG-BP is over-
expressed (46, 61, 64). However, it has recently been shown in a tissue culture model that loss of
MBNLl has a more drastic effect on mis-splicing, while the increased levels of CUG-BP had
only a secondary effect (26). This suggests that sequestration of MBNLl to the CUG and CCUG
repeats is the primary cause for the mis-splicing observed in DM.
To understand the function of MBNLlI in the disease state and during pre-mRNA
splicing, we characterized the RNA binding activity of purified recombinant MBNLll: We tested
binding to CUG and CCUG repeats, to a series of RNAs where portions of the CUG repeat are
mutated, and to a fragment from the cTNT pre-mRNA. We found that MBNLlI preferentially
binds short helical A-form RNA regions in both the CUG and CCUG repeats and the cTNT pre-
mRNA structure. In all cases the helical structures contain similar pyrimidine-pyrimidine
nucleotide mismatches. This suggests that MBNLlI may recognize and bind similar structures in
both the pathogenic repeats and in its pre-mRNA targets.
Results
The elongated zinc finger domains ofMBNLl are sufficientfor RNA binding
To characterize the RNA binding of MBNLll, we used a truncated version of MBNLlI
(containing amino acids 1-260). Recombinant protein was expressed in e. coli BL21 * cells, and
purified using and GST affinity tag and ion exchange chromatography. When compared to full-
length MBNLl (1-382), the truncated version of MBNL 11 (1-260) bound three different RNAs
with similar affinity: an RNA with 90 CUG repeats, a shortened CUG4 construct, and to a region
of the cardiac troponin T pre-mRNA (Figure 1 and Figure 5). Kino and colleagues also previously
found that two truncated versions ofMBNLlI (a.a. 1-248 and 1-269) bound RNA substrates in a
three-hybrid assay better than a full length version of MBNLll (65). MBNLll(I-260) contains
all four zinc fingers of the full length protein (Figure 1A), and was used for all of the studies
presented here and will be referred to as MBNLl throughout the remainder of the text.
Biophysical methods were used to characterize MBNLl. Analytical ultracentrifugation
(AUC) with purified recombinant MBNLl (Figure lB) was used to measure a molecular weight
of28.2 kDa (predicted molecular weight is 28.5 kDa). This indicates that MBNLl is a monomer
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Figure 1. Structural characterization ofMBNLl. (A) A schematic of MBNLl showing the
truncated form MBNLl(l-260) used in these studies. (B) Recombinant expressed
MBNLl has a molecular weight of28.5 kDa on a 10% SDS-PAGE gel. Note there is a
small amount of co-purifying contaminant with a molecular weight of approximately 55-
60 kDa. (C) Analytical ultracentrifugation ofMBNLl shows that it sediments with the
weight of a monomer. MBNLl has a slightly elongated shape, as its frictional ratio is
1.519. (D) Circular dichroism spectra ofMBNLl, showing a major peak at 203 and a
minor peak at 220 nm, indicating that a portion of MBNLl is disordered and MBNLl
lacks significant a-helical content in its structure (units ~£ are molar circular-dichroic
absorption).
in solution (Figure lC), as the zinc finger domains do not seem to mediate any oligomerization. It
may also be possible that the C terminal domain (amino acids 261-382) may mediate
oligomerization. The frictional ratio ofMBNLl was 1.5189. Globular proteins have a ratio of 1.2
(66), and an increased ratio is consistent with a protein that is elongated in solution. A co-
purifying contaminant (seen in Figure 1B), of approximately 65 kDa was also seen to sediment.
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However, the main peak at 28.2 kDa accounted for over 95% of the sedimented protein signal
(Figure 1C).
Circular dichroism (CD) was used to probe the secondary structure of MBNU (Figure
ID). The weak a-helical signal at 220 nm and the strong signal at 203 nm (indicative of disorder
in protein structures) suggests that MENU does not have significant a-helical structure, although
it is possible that MBNU contains some or significant ~-sheet structure, as the signal for this
structure was undetectable due to interference with the buffer. The addition of a known RNA
substrate did not alter the signal at 220 nm, suggesting no new a-helices were forming upon RNA
binding (data not shown). Mutations of individual cysteines within the zinc finger domains reduce
the stability ofMBNU and reduce its RNA binding affinity (data not shown), indicating that zinc
fingers competent to bind zinc are required for RNA binding. The addition of 5 IJ.M zinc chloride
did not alter the 203 nm to 220 nm ratio, indicating that the added ZnH caused no structural
changes in the protein and therefore that the four zinc finger domains were already saturated with
zinc ions (data not shown).
MBNLl hinds moderate and short CUG expansions with similar affinity
To identify a minimal CUG repeat construct that could be used for characterizing the
binding specificity of MBNU , we started with an RNA substrate containing 90 CUG repeats
(CUG90); this RNA was then truncated until a minimal RNA substrate capable of binding
MBNU was identified. In all assays, the protein was always in at least a ten fold excess of the
total number of CUG triplets, to ensure that multiple binding sites on the longer CUG expansions
would not artificially enhance the apparent affinity of MBNU for the longer repeats. To stabilize
the shorter CUG repeats that contained 8 repeats or fewer, an ultra stable UUCG tetraloop was
used to cap the short stem-loops (67). Stabilizing the short CUG repeats was likely necessary
because Miller and colleagues didn't observe binding with short CUG repeats (51), possibly
because in their experiments the shorter repeats were not forming stem-loops.
A stem-loop containing two pairs of CUG repeats separated by the tetraloop (CUG4)
bound MBNU with similar affinity compared to CUG90 (Figure 2A versus 2B). The slightly
reduced affinity ofMBNU for CUG90 compared to CUG4 may be because multiple MENU
proteins need to bind to CUG90 to cause a shift suggesting the apparent Kd for this RNA is likely
to be lower than 260 nM. Our truncation studies ofthe CUG repeats indicate that the minimal
binding site for MBNU is six base pairs or less.
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Thermal melts were performed to verify that the small RNA constructs formed the
predicted stem-loop structures. Discrete thermal transitions were seen for all RNAs constructs,
indicating that a stable stem-loop structure was indeed formed (see Table 1 for a listing of
estimated Tm values). In addition, the Tm of CUG4 was tested and found to be concentration
independent up to 2 j..LM, indicating that only an intramolecular structure formed at these
concentrations at the RNA concentrations used during our experiments (as opposed to
intermolecular structures which may start to form at higher concentrations and would likely have
a different melting curve).
MBNLl recognizes both the mismatch and Watson-Crick base-pairs within the CUG
repeat stem-loop
To determine the importance of the U-U mismatch in the CUG stem-loop RNA, we
replaced the U-U mismatch with other mismatches or placed Watson-Crick base pairs in this
position (see Figure 2). MBNLl binds to sequences containing any pyrimidine-pyrimidine
mismatch in any combination with similar affinity (apparent Kd values range from 140 to 170
nM) (Figure 2B, 2C and Table 1). The substitution ofpurine-purine mismatches (A-A, G-G and
A-G) for U-U mismatches all moderately inhibit the binding ofMBNLI by 10 to 20-fold (Figure
2D, 2E and Table 1). Replilcement of the U-U mismatch with C-A mismatches only reduces
binding approximately 4-fold while a G-U wobble base pair reduces binding more than 20-fold
(Figure 2F, 2G and Table 1). Replacing the U-U mismatches with Watson-Crick base pairs
almost completely abolishes MBNLl binding (Figure 2F), indicating the mismatch plays an
essential role in MBNLl 's binding.
The identity and location of the C-G and G-C base pairs in the CUG repeats are also
important for MBNLl binding. When the G-C base pairs in CUG4 were changed such that
cytosines were all one strand and the guanosines were all one strand, MBNLl binding was
reduced IS-fold (Figure 2H, lanes 1-6). Changing the polarity of the RNA from CUG to GUC
completely eliminated binding (Figure 2H), demonstrating that the polarity and order of the base
pairs in the sequence is important. Finally, an RNA with UCA repeats that form all Watson-Crick
base pairs capped with a UUCG loop does not interact with MBNLl (Figure 2H).
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Figure 2. MBNLI binds short CUG repeats with similar affinity to longer repeats and the
presence ofmismatches is necessaryfor binding. (A) MBNLl binding CUG90 repeats
(lanes 1-6) with an apparent Kd of 230 nm. The concentration of MENLl is shown above
each lane in !-tM in the gel shift assay. (B) MBNLl binding to pyrimidine-pyrimidine
mismatches. The sequence of the (CUG)4 RNA is shown below lanes 1-6. The boxed C-C
(lanes 7-12) and U-C (lanes 13-18) represent the replacement of the U-U mismatches
with these mismatches. (D) MBNLl binding to purine-purine mismatches in place of the
U-U mismatch, boxed sequence indicates mismatch replacement base pairs. (F) MBNLl
binding to G-U (lanes 1-6) and C-A (lanes 7-12) mismatches and Watson-Crick base
pairs in place of the U-U mismatches (H) Binding ofMBNLl to RNAs containing
sequence alterations to the Cytosine and Guanine positions in CUG4and a control RNA
with no sequence similarity to CUG repeats. (C, E, G, I) Binding curves.
TABLE 1. Apparent Kd and Tm values for all tested RNA constructs
Apparent Kd Tm
RNA construct (JAM) (OC)
CUG90 0.26 :t 0.05
CUG8 0.14 :t 0.04 60
CUG6 0.14 :t 0.04 61
CUG., 0.17 :.t 0.02 58
CCUGa 0.07 :.t 0.01 41
CCUG6 0.09 ± 0.01 41
CCUG" 0.12 ± 0.02 42
CCUG6-2 0.06 :.t 0.01 42
CXG" mismatch screen
Pyrimidine mismatch
u-u 0.17 :t 0.02 58
C-C 0.14 :t 0.03 53
U-C 0.15 :.t 0.03 53
Purine mismatch
A-G 1.4 :t 0.2 65
G..<J 4.2 :t 0.4 72
A-G 1.4± 0.4 67
Purine-pyrimidine mismatch
C-A 0.7 ± 0.1 69
G-U 6.5 ± 0.6 79
Watson-erick base pair
C-G >15" >95
A-U 11.5 :t 0.3 83
CUG" sequence alteration
CUCiGUG:l 2.5 :t 0.3 S3
GUCiGUC2 >lSiI S4
UCA2/AGU:l >15a 63
Intronic target
cTNTSOmer 0.022 ± 0.004 52
cTNT SOmer mutant 2.1 ± 0.3 34
cTNT 32mer 0.05 ± 0.01 58
cTNT 32mer G-U flip mutant 2.1 ± 0.3 61
Potential stem 11 1.00 :t 0.09 47,83b
Potential stem 12 0.22 ± 0.02 61
Potential stem 13 1.20 :t 0.07 54
i1KJ exceeds the highest protein concentration tested.
bthis RNA had two discreet thermal transitions.
16
17
Thermal melts were again performed on all RNA constructs, to verify secondary
structures formed (Table 1). All RNA structures were relatively stable, with Tms greater than 50
°C. Analysis of the range of the transitions indicates that all RNA structures should be fully intact
at 25°C, the temperature at which all binding studies were performed.
MBNLl binds short CCUG stem-loops
A series of short CCUG RNA constructs with 4, 6 and 8 repeats were designed and
named CCUG4, CCUG6 and CCUGg, respectively (all which also contained a tetraloop to act as a
cap). MBNLl bound all three RNA constructs with similar affinity and on average with 2-fold
stronger affinity compared to CUG repeats (Figure 3 and Table 1). CCUG expansions can anneal
in two possible structures (Figure 3A). Presently, CCUG expansions are thought to be in the first
structure (42, 43), where two C-G base pairs are interspaced by two U-C mismatches. CCUG
repeats are thermodynamically predicted by Mfold to be in this structure (44).
However, another structure is possible in which G-C base pairs are flanked by alternating
U-U and C-C mismatches. A CCUG6 construct was designed that forced the stem-loop to anneal
in this alternate structure (CCUG6_2, Figure 3A). MBNLl bound this construct with slightly
enhanced affinity compared to CCUG6, indicating that MBNLl binds CCUG expansions in either
configuration but may have a slight preference for the conformation containing the alternating U-
U and C-C mismatches. Melting studies performed on the CCUG stem-loops showed lower Tms
than those for the CUG stem-loops (Table 1), which reflects the decreased stability of these
structures due to the increased proportion of mismatches in the structure.
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Figure 3. MBNLl binds CCUG expansions with high affinity, in two possible registers. (A)
MBNLl binding to CCUG4 (lanes 1-6), CCUG6 (lanes 7-12) and CCUG repeats in an
alternate register (labeled CCUG6_2) in lanes 13-18. Concentration of MBNLl is in IlM
labeled above each lane. (B) Binding curve for CCUG constructs.
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MBNLl binds a helicalA-form structure within the cTNTpre-mRNA
It has been previously shown that MBNLl can be cross-linked to the 3' end of the fourth
intron of the cardiac troponin T (cTNT) pre-mRNA in vitro (28). However, quantitative binding
to this substrate has not been performed. We found that MBNLl binds a 50 nucleotide fragment
from the 3' end of the intron (cTNT SOmer) with the highest affinity of any of the RNAs we
tested, with an apparent KJ of22 nM (Figure 4C and D). This SOmer spans nucleotide residues 8
through 58 directly upstream of exon 5 (Figure 4A). The full1ength MBNLl1 (1-382) bound the
cTNT SOmer with similar affinity to MBNLl(1-260) (Figure 5).
Because MBNLl was found to bind short stem-loop RNAs, we hypothesized that the
cTNT SOmer might also contain a short stem-loop recognized by MBNLl (Figure 4B). UV
melting shows that the cTNT SOmer unfolded with a single transition and a Tm of 52 DC (Figure
4E), indicating at least one structural element within the RNA. As CUG repeats are known to be
A-form (40), we analyzed the circular dichroism (CD) spectrum of the cTNT SOmer and the
CUG4 stem-loop RNA to determine if this structure was also A-form in nature. A-form duplex
RNA has a characteristic peak between 260-270 nm in a CD spectrum, while single stranded
RNA has a peak at approximately 275 nm (68, 69). The cTNT SOmer (1 !1M) had a peak at 271
nm and CUG4 (1 !1M) had a strong peak at 269 nm (Figure 4F). These values are in the higher
range of the duplex A-form range, but currently only the CD spectrum of purely duplex or single
stranded RNA has been characterized, and the mismatches in the CUG4 stem and potential
mismatches in the cTNT stem structures may shift the peak. Because the cTNT SOmer has a peak
at a similar wavelength, it indicates that its stem structure is similar to the CUG4 stem.
Addition ofMBNLl (1 !1M) to the cTNT SOmer decreases the signal by 23% with the
peak shifting to 272.5 nm. Both the reduction in signal and shift suggest that MBNLl binding
alters the RNA structure in some way that may reduce the base stacking of the RNA. MBNLl has
no signal at 270 nm (Figure 4F), meaning the change in signal is due solely to structural changes
in the RNA. Approximately 85% ofthe RNA is predicted to be bound at these RNA and protein
concentrations, indicating that the peak shift and the 23% decrease in signal is not stoichiometric,
but only a partial decrease in signal by the majority of the RNA population.
The addition of 1 !1M MBNLl to CUG4 similarly decreased the CD signal by 20% and
caused a peak shift of2.5 nm, from 269 to 271.5 nm (Figure 4G). The GUC4 (l !1M) construct
was tested and had a signal at 270 nm, which was unchanged in the presence of 1 !1M MBNLl
19
A
Intron4 ~-IExon41--Ij~
----- ----
--- --
- - - cTNT 50mer construct :- - - - -
J I --5~::~::r::~t~ UGU\CUC :live palY~YllmidinetractG/CUGC GGC CAC UCC CUG~C cuc ~f
3' splice site
MBNL cross-linking sites
B
cross~
linking
sites
MBNL(PM)
r:,<::>"> r:,':' <::,'?,!f.Jr
'11'>'\'1'-
D
....---
E
t-' 0,51
'0 0,8 / E 0,5~ OJ; r c:~0,49~ Ia: 0.4 /1 i046 Tm,52'C'~ 0.2 0,47
u. 0
_.......
«
0,460.001 0,01 0,1 20 40 60 80 100
MBNL(PM) Temperature 0 C65432
c
F CD spectrum of cTNT 50mer
12
9,
6:
W
<1 3 ;
2611 280 300 320
Wavelength (nm)
G
18 ,
15 f
12 '
W 9;
<16 i
260 280 :JOO 320
Wavelength (nm)
H 5
W 2,
<I
1
-1
2411 260 260 3110 320
Wavelength (nm)
Figure 4. MBNLI binds a structured region in the 3' end ofintron 4 in the human cardiac
troponin T (cTNT) pre-mRNA. (A) A schematic ofintron 4 of the cTNT pre-mRNA.
The cTNT 50mer used for binding studies is indicated, (B) A schematic model of
MBNLl binding this RNA as stem-loop. (C) Binding ofMBNLl to cTNT 50mer with
the concentration of protein labeled above each lane. (D) Binding curve of cTNT 50mer.
(E) Thermal melt of the cTNT 50mer, with a Tm of 52°C. (F) Circular dichroism (CD)
spectra of the cTNT 50mer with and without MBNLl present (units 11£ are molar
circular-dicroic absorption). (G) CD spectra of CUG4 with and without MBNLl present.
(H) CD spectra of GUC4 with and without MBNLl present.
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Figure 5. A truncated version ofMBNLI has similar RNA binding activity compared to the
full length protein. (A) Full length recombinantly expressed MBNLl(1-382) with the
GST affinity tag has a molecular weight of 67.5 kDa and MBNLl (1-260) without the
affinity tag has a weight of28.5 kDa on a 10% SDS-PAGE gel. Note, in the MBNLl(1-
382) sample there are moderate amounts of 4 smaller degradation products with
molecular weights of approximately 55, 50, 30 and 27 kDa, as well as small amounts of
contaminating GST with a molecular weight of 26 kDa. The tag was kept on MBNLl (1-
382), as it was more stable and degraded less, which was not a problem with MBNLl(1-
260), where the affinity tag was removed. The concentration ofMBNLl(1-382) could
only be approximated, as the sample is not completely pure. The approximation made
was that equal concentrations ofMBNLl(1-382) and MBNLl(1-260) were loaded on the
gel shown. (B) Binding assay with CUG90 for MBNLl(1-382) and MBNLl(1-260). (C)
Quantitation ofCUG9o gels. (D) Binding assay with CUG4. (E) Quantitation ofCUG4
gels. (F) Binding assay with 50 base region of the cTNT pre-mRNA (cTNT SOmer). (G)
Quantitation of cTNT SOmer gels.
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(Figure 4H). The relative amplitude differences between cll'JT SOmer, CUG4 and GUC4 are
likely due to differences in base stacking due to sequence differences.
MBNLl binds a stem-loop containing mismatches at the 3' end ofthe 4th cTNT intron
To determine the structure of the putative stem-loop in intron 4 of the cTNT pre-mRNA,
mung bean nuclease was used to probe the secondary structure. A shortened version of the cTNT
RNA (cTNT 32mer) was used in the structure probing assay because the cTNT SOmer was less
stable in these assays and degraded more easily. MBNLl binds the cTNT 32mer with high
affinity, with an apparent Kd of 50 nM (Table 1).
Mung bean nuclease is a non-specific single-stranded cutter that cleaved residues 12 to
22 and 30-31, while most of the other residues were not. This suggests that residues 12-22 are
likely single-stranded and located within a loop, with the final three residues being in a 3' tail
(Figure 6A). Residues 4-11 and 22-29 are protected except position 8 is cleaved at a low level
(lane 3), indicating these two regions form the stem (Figure 6B).
This cleavage pattern suggests the two MBNLl sites identified through cross-linking (28)
come together to form the stem. Therefore, it appears that these two separate sites, underlined in
Figure SB, are actually one individual site (Figure 6B). Three different base pairing
configurations are possible for this stem containing slightly different base pairing and mismatches
possibilities (Figure 6C-D). To determine which (if any) ofthe three stems are favored by
MBNL1, we created three stems with the different base pairing configurations capped with the
UUCG tetraloop (Figure 6D). MBNLl bound all three RNA structures, but it clearly prefers stem
#2. MBNLl bound this RNA with 5-6 fold greater affinity compared to stems #1 and #3, with an
apparent Kd of 0.22 !lM for stem #2. This Kct is in the same range as the Kct for the CUG4 RNA,
although it is 4-fold weaker than the endogenous cTNT 32mer. This suggests that Stem #2 is the
preferred structure that MBNLl binds in the endogenous pre-mRNA target but that loop or tail
regions may make additional contacts with MBNLI. Alternatively, the UUCG cap may perturb
the structure of RNA in a way that negatively effects MBNLl binding.
Thermal melts were performed on these stem-loops, and stem #2 was found to have the
highest Tm, suggesting it is the most stable stem and likely the biologically relevant structure.
However, the stabilities of these stems were likely altered by the presence of the UUCG cap. For
instance, stem #1 had a second discreet transition at 83°C (Table 1). It is likely that stem #1 has
two separable structural elements, separated by the C bulge and U-C mismatch (Figure 6C). The
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UUCG cap is known to form a stable fold with just two adjacent G-C base pairs (67), making it
likely that the second structural element of stem #1 is strongly stabilized by this cap, which is not
part of the wild-type sequence.
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Figure 6. MBNLI binds the cTNT 32mer as a stem-loop. (A) Mung bean nuclease cleavage
pattern of cTNT 32mer. The concentration of mung bean nuclease is 100, 10, and 1 units
per ilL, in lanes 2-4 respectively. (B) Schematic of the likely stem-loop within cTNT
intron 4, showing cleavage locations of mung bean nuclease. Larger shapes indicate
strong cleavage events while smaller shapes represent weak cleavage events. The cross-
linking sites determined previously are boxed (28). (C) Binding curve of the three
potential stem structures of the cTNT intron 4, showing MBNLl prefers structure #2. (D)
Gel shifts showing MBNLl binding to the three potential stems of cTNT intron 4.
Concentration of MBNLl is labeled above each lane, note the lower concentrations in
lanes 8-12 compared to lanes 2-6 and lanes 14-18. Sequences highlighted in grey are
sequences from the cTNT intron in the three different potential base pair and mismatch
configurations. The non-grey sequence is the tetraloop cap and an additional base pair to
stabilize the structure if necessary.
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Mutations that destabilize the stem in the cTNT 4h intron also significantly reduce
binding ofMBNLI
We hypothesized that the stem loop structure in the cTNT RNA was critical for MBNLl
binding and that mutations that destabilize the stem loop would abolish MBNLl binding.
Previously, Ho and colleagues found that four simultaneous Guanosine point mutations (which
will be referred to as the 4G construct) in this region of the cTNT 4th intron reduce MBNLl 's
ability to cross-link to this RNA and the ability of MBNLl to negatively regulate the inclusion of
the downstream exon is eliminated (28). These four point mutations change four of the six
guanosines that participate in base pairing or wobble base pairing in the stem loop we identified
(Figure 7A).
The 4 mutations in the cTNT SOmer reduced binding ofMBNLl approximately 100-fold,
the Kd changed from 23 nM for the wild-type cTNT RNA to 2.1 IlM for the mutant RNA (Figure
7B-C, Table 1). This result is consistent with the nearly complete reduction of MBNLl cross-
linking to this mutant RNA (28). A UV melt showed that these mutations significantly reduced
the stability of the RNA structure within the cTNT RNA, as expected. The Tm was shifted from
S2°C to 34°C for the mutant RNA (Figure 7D). The CD spectra of the cTNT SOmer mutant was
also different from the wild-type cTNT RNA, with the mutant having a reduced signal and the
peak shifted to 27S nm, into the known single stranded RNA wavelength region (Figure 7E).
Addition ofMBNLl (lIlM) reduced the peak only 4% (compared to a 23% reduction of the
wild-type sequence) and did not shift the peak wavelength. These results suggest that the stem-
loop structure within the cTNT pre-mRNA is the recognition site for MBNL1.
Regulated splicing by MBNLI requires a stem-loop containing a MBNLI binding site
To test the role of the stem-loop in vivo, a cTNT minigene that includes exons 4-6 (28)
was used to make mutations in the MBNLl binding site and monitored for changes in the splicing
of the cTNT minigene in HeLa cells containing MBNLl (51). To determine if splicing ofthe
mutated MBNLl binding sites changed upon MBNLl sequestration, a plasmid expressing 9S0
CUG repeats was co-transfected into the ReLa cells. We reproduced the results ofRo and
colleagues showing that MBNLl regulates the splicing of the wild-type cTNT
minigene (Figure 8B and 8C), finding that exon S inclusion shifts from 66% to 89% when
MBNLl is sequestered by the CUG repeats. When the four guanosines are mutated to cytosines
(4G mutations) MBNLl no longer regulates the splicing of this cTNT minigene.
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Figure 7. Four point mutations destabilize the stem in the cTNT 50mer and reduce MBNLI
binding. (A) Schematic of the stem-loop with the four point mutations indicated by
arrows. (B) Gel shift assay shows MBNLl binding to the mutated SOmer. (C) Binding
curve ofMBNLl to the mutant cTNT SOmer. (D) UV melt of the cTNT SOmer mutant,
with a Tm of 34°C. (E) Circular dichroism spectra of the cTNT SOmer mutant alone
(l ~M) and with MBNLl (l ~M).
The 4G mutant had slightly reduced exon 5 inclusion, 57% compared to 66% for the
wild-type sequence (Figure 8B). This reduction in exon 5 inclusion is an unexpected result, as the
point mutations both disrupt the stem-loop and MBNLl binding, which should cause an increase
in exon 5 inclusion. However, these point mutations create a large new single stranded element in
the pre-mRNA, and this structural change might have unanticipated effects, such as the
recruitment of other protein factors, or the creation of an unknown silencing element. Upon co-
transfection with the DMPK-CUG950 minigene, no change was seen in exon 5 inclusion with this
construct (Figure 8C-D), indicating that once MBNLl 's binding site is abolished, the splicing of
this construct is independent of MBNLl. Ho and colleagues also observed this surprising result
with the 4G mutant minigene (28).
To determine if a stem-loop that contains CUG repeats similar to the CUG4 construct
would function to recruit MBNLl, the upper portion of the stem was replaced with two CUG
repeats on each side (CUG stem - CUGS, Figure 8A). This CUGS minigene was regulated by
MBNLl. In the presence ofMBNLl only 29% inclusion of exon 5 was observed (Figure 8B)
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Figure 8. The sequence and structure ofthe cTNTstem-loop upstream ofexon 5 is
importantfor regulated splicing by MBNLI. (A) Schematic of mutations made to the stem-loop
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representation of exon 5 inclusion for the different constructs with and without the
overexpression of the 950 CUG repeats.
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while sequestration of MBNLl by the CUG950 RNA leads to 41 % of the exon 5 inclusion. The
lower percentage of exon 5 inclusion compared to wild-type and the weaker effect of MBNLl
regulated is likely due to the stability of the stem-loop being different between these two RNAs.
Further strengthening the stem-loop with two additional base pairs, one at each end of the
helix (Figure 8A, Stem Strengthen - SS), almost completely inhibited the use of exon 5 both in
the presence of MBNLl and when it was sequestered (Figure 8B-D). This result indicates that a
strong stem-loop inhibits the use of the 3' splice site and the binding of MBNLl probably does
not enhance the effect because the stem is sufficient on its own, while the weaker stems (wild-
type and CUGS) can be melted by the splicing factors binding at the 3' end ofthe intron.
The in vitro binding experiments demonstrated that MBNLl prefers to have purines on
both sides of the helix and therefore we predicted that altering the cTNT stem-loop in a manner
that shifted all the purines to one side and the pyrimidines on the other side would result in an
MBNLl unregulated exon. This was done by flipping a G-U b'ase pair (G-U flip - GUF, Figure
8A). This change results in complete inclusion of exon 5 (99%) in the presence or sequestration
ofMBNLl (Figure 8B-D). As expected this RNA is bound weakly by MBNLl (Table 1, a 42-
fold decrease in binding compared to cTNT 32mer). The complete inclusion of exon 5 is likely
the result of strengthening the poly-pyrimidine tract, which is recognized by the constitutive
splicing factor U2AF65.
Discussion
MBNL1's structure and its lack ofcooperative RNA binding
The AUC and CD experiments with MBNLl suggest the protein adopts a slightly
elongated structure. When monitored by CD, the a-helical structure of MBNLl does not appear
to significantly alter upon the addition of CUG4, although other structural components have yet to
be measured upon RNA binding. We propose MBNLl, like other zinc finger proteins, is
organized into domains around each zinc ion, and that each domain contacts the RNA in a
relatively independent manner (70-73).
The lack of significantly higher affinity binding to longer CUG repeats suggests that
MBNLl does not bind in a highly cooperative manner to CUG repeats. An analysis of our
binding data supports this conclusion. Scatchard and Hill plots (data not shown) reveal MBNLl
binds CUG90 with only minimal cooperativity (Hill constant of 1.4) under the binding conditions
used in these studies. Analysis of the other repeat RNA substrates indicates only very weak
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cooperativity, and for cTNT SOmer there is no evidence for cooperative binding at all. These
results suggest this version ofMBNLl recognizes the many binding sites on long CUG repeats as
independent binding sites.
It should be noted that the apparent Kds reported here are dependent on our binding
conditions: 175 mM NaCl, 5 mM MgC}z, 20 mM Tris (pH 7.5), 1.25 mM BME, 12.5% glycerol,
2 mg/ml BSA and 0.1 mg/ml Heparin. These conditions are quite stringent and the apparent ~s
are lowered if NaCl, Heparin concentrations or temperature are decreased in the binding
conditions. If we perform binding studies under these less stringent conditions our apparent ~s
for CUG repeats are similar to those measured by Yuan and colleagues (74).
The RNA binding specificity ofMBNLl for CUG and CCUG repeats
Analysis of RNA substrates in which the CUG repeat tract sequences are modified in
various ways (Figure 2) clearly shows the preference of MBNLl for pyrimidine-pyrimidine
mismatches as well as the Watson-Crick base pairs in their particular positions. The requirement
of mismatches for MBNLl binding could be due to two different reasons; either the mismatches
are directly recognized by MBNLl or the mismatches allow the helix to be easily distorted so
MBNLl can gain access to the C-G and G-G base pairs.
Both the specific recognition and structural distortion are likely playing a role in MBNLl
binding the CUG repeats. The distortion is supported by the decrease in CD signal and the peak
shift upon MBNLl binding to the CUG repeats and the cTNT SOmer (Figure 4). Furthermore,
there also appears to be a general inverse trend between MBNLl binding affinity and the stability
of the RNA structure. All the RNA substrates to which MBNLl binds with strongest affinity
generally have lower Tm values (Table 1). The CCUG substrates, as a group, have the strongest
affinity for MBNLl and also have the lowest Tm values. The pyrimidine-pyrimidine mismatches
also, as a group (Table 1), have the lowest Tm values for RNAs containing a mismatch, as well as
the strongest binding affinity for MBNLl. This trend further suggests that MBNLl alters the
structures of the RNAs when it binds. If more energy is required to distort or disrupt the base
pairing interactions of the RNA, it might result in weaker binding by MBNLl.
MBNLl binds CCUG repeats with approximately 2-fold stronger affinity in both
structural conformations (Figure 3) compared to the CUG repeats. Previously, Kino and
colleagues also qualitatively found that MBNLl preferred CCUG repeats over CUG repeats.
These results are surprising because patients with DM2 tend to have more CCUG repeats
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compared to patients with CUG repeats (75). Additionally, the ZNF9 pre-mRNA containing the
CCUG repeats appears to be expressed at similar or even higher levels than the DMPK pre-
mRNA (50, 76). Yet, the symptoms ofDM2 patients are less serious than those ofDMl patients
(77). This supports the model that the expanded CUG repeats, unlike the CCUG repeats, are
affecting transcription or other processes in the cell and create another layer of mis-regulation in
DMI compared to DM2 (21).
Recognition ofa helical element within the cTNTpre-mRNA by MBNLl
Our observation that MBNLl binds short stem-loops prompted us to consider that
MBNLl might recognize a short stem-loop within the cTNT pre-mRNAs as well. We chose to
study the cTNT intron 4 because it was the only available pre-mRNA substrate with a well
identified binding site (28). The combination ofUV melting of the cTNT SOmer RNA (Figure
4E), CD of this RNA in the absence and presence ofMBNLl (Figure 4F) and structure probing of
the cTNT 32mer (Figure SA-B) show that this RNA folds into a stem-loop structure which
appears to be partially A-form, which was also found for the CUG repeats. This proposed helix
has some similarities to the CUG and CCUG helices in that one of the pyrimidine-pyrimidine
mismatches is bracketed by G-C base pairs (though the other mismatch is flanked by G-U wobble
base pairs). The similarities between the CUG, CCUG and cTNT stems suggest MBNLl
recognizes both its pathogenic and natural RNA targets through an analogous mode of
recognition.
The stem-loop structure in the 4th intron of the cTNT pre-mRNA is not predicted by m-
fold, perhaps due to its multiple mismatches and the minimal number of consecutive base pairs. It
was therefore previously predicted to be single stranded. As stated above, our data strongly
support the formation of this stem-loop and that MBNLl recognizes this RNA structure. The lack
of binding to the cTNT SOmer containing the four mutations due to the disruption of the stem-
loop and potential removal of key nucleotides for MBNLl recognition (Figure 7), further support
the model that MBNLl binds this stem-loop. The lack of cross-linking by MBNLl to a cTNT
RNA containing these four mutations as well as the elimination of regulated splicing of the cTNT
exon S when these mutations are introduced into a cTNT minigene (28); suggest the presence of
this stem-loop within intron 4 of the cTNT pre-mRNA is important for the regulated splicing of
exon S by MBNLl.
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Clearly MBNLl can bind a range of RNA stems, but the common theme of pyrimidine-
pyrimidine mismatches and presence of G-C and C-G base pairs indicates these are requirements
for binding by MBNLl. Further studies are necessary to fully define the specificity of MBNLl
before predictions can be made to identify binding sites in other MBNLl regulated pre-mRNAs.
Another challenge is that these potential regulatory stem-loops will not necessarily be predicted
by folding programs due to the lack of consecutive base pairs and presence of mismatches as
observed for the cTNT intron 4 stem-loop.
MBNLl's binding to a helical element in its role as a splicing regulator
A possible model for the mechanism through which MBNLl regulates the exclusion of
exon 5 in the cTNT mRNA is that MBNLl competes for binding of the intron with other splicing
factors. When MBNLl binds the stem-loop at the 3' end of the intron, the presence of MBNLl or
the stabilization of the stem-loop may inhibit recognition of this 3' splice site by the splicing
machinery causing exon' skipping to occur. If the stem-loop does not form and MBNLl is not
present, the splicing machinery recognizes this site and exon 5 is included (Figure 9).
The mutations made to the cTNT splicing minigene support the model that recruitment of
MBNLl to a stem-loop causes repression of exon 5. The replacement of the endogenous binding
site with another sequence that MBNLl binds causes MBNLl dependent repression of exon 5,
while minor mutations that significantly reduce MBNLl 's binding abolishes MBNLl ability to
repress inclusion of exon 5. These results indicate that direct binding of MBNLl to this stem-loop
is required for the repression of exon 5. Mutations that add additional base pairs that stabilize the
stem-loop also strongly cause repression of exon 5, showing that increased stability of the stem
correlates with repression of exon 5. It appears that if the stem is strengthened enough, MBNL1 is
no longer needed for repression, as sequestering MBNLl function does not affect splicing of this
construct.
This mechanism may have two levels of regulation. First, the stem-loop alone might
inhibit the use ofthis 3' splice site; second, the addition of MBNLl might further stabilize this
stem-loop and increase the block at this 3' splice site. Previously, stem-loop formation has been
shown to reduce the use of 5' and 3' splice sites (78, 79), but this is the first example to our
knowledge in which the stem-loop is specifically recognized by a factor that regulates splicing.
Therefore MBNLl may be a member of a new second class of splicing regulators utilizing
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secondary structure, while other splicing regulators have previously been shown to recognize
single-stranded motifs, such as the SR splicing factors (for review see (80,81)).
Like other factors regulating splicing, MBNLl functions in one context to exclude an
exon as described for the cTNT exon 5, while for other exons the presence of MBNLl enhances
the inclusion of a particular exon. One possible mechanism through which MBNLl could
enhance exon inclusion would be to sequester exonic or intronic splicing silencers in a stem-loop.
Alternatively the location ofMBNLl binding (upstream or downstream of the exon or within the
exon) may determine ifit acts as splicing enhancer or repressor as has been found for other
splicing factors, such as NOVA (82).
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Figure 9. Model ofMBNLI's regulation ofthe cTNTpre-mRNA splicing. (A) If the stem-
loop doesn't form the splicing machinery represented by U2 (U2 snRNP) recognizes this
3' splice site and exon 5 is included. (B) When the stem-loop forms and MBNLl binds,
this 3' splice site is not recognized by the splicing machinery and exon 5 is skipped.
Materials and methods
Cloning and protein purification. MBNLll was PCR amplified and was cloned into GST fusion
vector pGEX-6P-I (Amersham), using DNA (MBNLl isoform with amino acids 1-382) provided
by Maury Swanson (28). Both the full length MBNLll and MBNLll(l-260) constructs were
cloned using BamHI and Not! restriction sites.
Using BL21-Star expression cells (Invitrogen), protein expression was induced with 0.25
mM IPTG at an OD6oo ~ 0.5-1, for 3-4 hours at 3TC. Cells were lysed in 30 mL of buffer (500
mM NaCl, 25 mM Tris pH 7.5, 10 mM ~-Mercaptoethanol(BME) and 5% glycerol) using 1
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mg/ml of lysozyme followed by sonication (3 x 30 seconds). Cell extract was centrifuged for 15
minutes at 17,000 rpm, and lysate which contained GST-MBNLl was collected. GST-MBNLl
was bound to GST affinity beads for 30 minutes at 4°C. Beads were washed 5 times with buffer
(lM NaCI, 25 mM Tris pH 7.5 and 5mM BME); MBNLl was cleaved from the affinity tag with
Precision Protease (Amersham) and collected from the beads. The protein was then run over an
anion exchange (Q) column. Co-purifying contaminants bind the column, but MBNLI does not.
MBNLl was collected in the column flow through, concentrated and dialyzed into storage buffer
(50% glycerol, 500 mM NaCI, 20 mM Tris pH 7.5,5 mM BME) and stored at -20°C.
RNA synthesis, labeling andpurification. The RNA substrates CUG90 and CUG54 were
transcribed with T7 polymerase offthe pCTG54 and pCTG90 plasmids, respectively, provided by
Maury Swanson (51). During transcription, RNAs were radiolabeled using [u)2P]CTP. All other
RNA substrates were ordered from IDT DNA, and 5' end-labeled using [y)2p]ATP. All RNAs
were purified on 8% poly-acrylamide denaturing gels.
Gel shift assay. Solutions for the protein-RNA binding experiments contained 175 mM NaCl, 5
mM MgCh, 20 mM Tris (pH 7.5), 1.25 mM BME, 12.5% glycerol, 2 mg/ml BSA and 0.1 mg/ml
Heparin. Prior to incubation, RNA substrates were annealed by incubation at 95°C for 2 minutes
and then placed directly on ice for 20 minutes in 66 mM NaCl, 6.7 mM MgCb, and 27 mM Tris
(pH 7.5). Protein was then added to the RNA. The binding reaction was 10 ~L volume and was
incubated for 20 minutes at room temperature before 3-5~L were loaded on a pre-chilled 4°C
gel. RNA and RNA-protein complexes were separated on 3% acrylamide (37.5:1, or 80:1),0.3%
agarose, 0.5x Tris-Borate (TB) gels, run for approximately 30 minutes at 4°C, 175 volts. Gels
were dried and autoradiographed.
For binding curves, gels were quantified using ImageQuant (Molecular Dynamics). The
percent RNA bound was determined by taking the ratio of RNA:Protein complex to total RNA,
per lane. Binding curves were graphed and apparent Ki values were determined with
KaleidaGraph (Synergy) software using the following equation: y=((m2 + ml + mO)-((-m2 - ml -
mO)2-(4 x ml x mO))0.5/(2 x ml), where y=% bound, m2= Ki, ml=total RNA concentration and
mO=protein concentration. This equation assumes a 1: 1 interaction between the RNA and protein,
which allows only an apparent Ki to be determined for CUG90 and RNAs containing more than
one binding site. To determine the standard error of the apparent dissociation constants, 3-5
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binding titrations were performed with each substrate and the apparent:Ki values determined for
each titration separately, prior to averaging. The error bars on the binding curve were obtained by
averaging the individual titration points and calculating the standard deviation. Data points
greater than two standard deviations from the average were discarded, with at least three data
points remaining for standard deviation analysis.
Structure probing assay. End-labeled RNA was incubated in the presence of protein or buffer for
20 minutes at room temperature, using the same binding conditions used for the gel shift assay
(except BSA was excluded and 0.1 mg/ml tRNA was used instead of heparin, and the volume of
the binding reaction was 9 ~L). RNases (1 ilL) were added, and the RNA digested for 2 minutes
at room temperature. The reaction was quenched with phenol; RNA was collected through
ethanol precipitation, re-suspended in denaturing dye and heated at 95°C for 10 minutes. The
sample was then run on a 15% poly-acrylamide (19:1), 8M Urea, Ix TBE gel.
Analytical ultracentrifugation (A UC). AUC runs with MBNLl (20 11M) were made in solutions
containing 170 mM NaCl, 20 mM Tris (pH 7.5), BME 0.2 mM and 1% glycerol (v/v). Data was
collected on an Optima XL-I (Beckman), for ~10 hours at 60,000 rpm, 4°C. Data was analyzed
using SedFit 97 (NIH).
Circular dichroism (CD) and thermal melts. The CD spectra of MBNLl (211M) were measured
in 50 mM NaCI and 10 mM sodium phosphate buffer (pH 7.5). Data was collected on a I-nO
spectropolarimeter (Jasco) for 0.5-1 hour at room temperature at a rate of 5 nm/min. For the CD
spectra of RNA, the samples were annealed by snap-cooling (95°C for 2 minutes, then directly
on ice for 15 minutes) in 50 mM NaCl, 5 mM MgCh and 10 mM phosphate (pH 7.5); lower salt
and phosphate were used to reduce interference at lower wavelengths. CD measurements were
made at room temperature over a period of 2-3 hours, at spectral scanning rates of 5 or 10
nm/min. For measurements on protein-RNA complexes the components were mixed and
incubated for 20 minutes prior to data collection.
For the CD thermal melt, RNA was prepared as normal and heated at a rate of 2°C per
minute. For UV thermal melts, RNAs (111M) were snap-annealed and melted at a rate of2 °C per
minute, monitored at 260 nm. Tm values were calculated by determining the inflection point for
each thermal transition, or the mid-point of the transition if the inflection point was not apparent.
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In vivo splicing. Wild-type cTNT, the 4G cTNT mutant, and the DMPK-CUG950 minigenes were
obtained from the lab of Thomas Cooper (28). All additional mutations were made using PCR
from the WT sequence. SaIl and Spel restriction sites were used to sub-clone all mutants after
PCR.
HeLa cells were grown in monolayers in DMEM with GLUTAMAX (GIBCO) and
supplemented with 10% fetal bovine serum (GIBCO). Approximately 2.0 (± 0.2) xl0s cells were
plated in 6 well plates and transfected 18-20 hours later at 70-90% confluency. 1 ug ofplasmid
was transfected into each well of cells, using 5 uL of Lipofectin2000 (lnvtitrogen) according to
the manufacturer's protocols. For co-transfection, 1 ug of total plasmid was transfected, at 500 ng
of each construct. Cells were harvested 20-24 hours after transfection using triplE reagent
(GIBCO). Immediately following harvesting, RNA was isolated from the cell pellets using an
RNeasy kit (QIAGEN). 500 ng of isolated RNA was DNased with RQI DNase (Promega)
according to manufacture's protocol. 100 ng of DNased RNA was reverse transcribed with
Superscript II and a cTNT-specific reverse primer according to manufacturer's protocols. 30 ng
of the RT reaction was subjected to 22-25 rounds ofPCR amplification using cTNT specific
primers spiked with a kinased cTNT forward primer. The linear range for PCR was determined
for the WT and 4G construct and found to be between 20-26 cycles. The resulting PCR products
were run on a 6% (19:1) poly-acrylamide denaturing gel at 6W for 2 hours. The gel was
subsequently autoradiographed and quantitation of the radioactive bands was performed using
ImageQuant software. T-Tests were performed in Excel, assuming two distribution tails using a
homoscedatic model.
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CHAPTER III
THE PROTEIN FACTORS MBNLI AND U2AF65 BIND
ALTERNATIVE RNA STRUCTURES TO REGULATE SPLICING
Contribution note: this chapter is previously published (Warf et al., 2009) (132). The other
contributors were Julien V Diegel, Peter H von Hippel and 1. Andrew Berglund. Julien V
Diegel performed afew experiments, and Peter H von Hippel and 1. Andrew Berglund helped
with experimental design, data analysis and manuscript preparation.
Introduction
Alternative splicing is a fundamentally important process that many organisms use to
increase proteomic diversity. Many diseases are known to arise from the mis-regulation of
alternative splicing (18). Myotonic Dystrophy (DM) is an example of a disease where the
alternative splicing of many pre-mRNAs is mis-regulated. The mis-splicing seen in DM is
thought to be caused, at least in part, by the mis-localization of the splicing factor MBNLl (21,
22, 84). MBNLl is known to interact directly with three pre-mRNAs that are mis-regulated in
DM, the cardiac troponin T (cTNT) (28, 85), fast troponin T (74), and SERCAI (86). It is unclear
how many more ofthe mis-regulated pre-mRNAs observed in DM may also be directly bound
and regulated by MBNLl.
We have recently shown that MBNLl binds a stem-loop within intron 4 of the cardiac
troponin T (cTNT) pre-mRNA. This stem-loop is located directly upstream of exon 5, which is
mis-regulated in this disease (28, 85). The mechanism used by MBNLl to repress exon 5 remains
undetermined. One mechanism might entail a direct binding competition between MBNLl and
other splicing factors. One of the best articulated models of the regulation of alternative splicing
is sex determination in Drosophila melanogaster, where the protein Sex Lethal (Sxl) competes
wi th the splicing factor U2AF65 at the 3' end of certain introns (reviewed in (87)). U2AF65 is
thought to be one of the first splicing factors to bind an intron and thus helps define the 3' end of
the intron. In concert with other proteins that bind near the 3' end, U2AF65 is responsible for
helping to recruit the U2 snRNP to the branch-point sequence (7, 8, 88). When Sxl inhibits
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U2AF65 binding and the subsequent recruitment of the U2 snRNP, the spliceosome selects
another 3' splice site, or the intron is retained if another 3' splice site cannot be defined (88, 89).
We hypothesize that MBNLl may act through a similar mechanism to compete with.
U2AF65. U2AF65 is a potential competitive target ofMBNLl because a putative U2AF65
binding site appears to be in the loop portion ofthe stem-loop which MBNLl binds (84). We
found that MBNLl does compete with U2AF65 for binding of a region within intron 4. This
competition with U2AF65 is functionally important, as recruitment of the U2 snRNP is reduced
by MBNLl. Furthermore we found that MBNLl and U2AF65 compete by binding mutually
exclusive RNA structures.
Results
U2AF65 recognizes a canonical sequence within intron 4 ofthe cTNTpre-mRNA
We have previously shown that MBNLl binds a stem-loop located at the 3' end ofintron
4 (Figure lA-B) (84). A putative poly-pyrimidine tract (py-tract) for intron 4, the likely U2AF65
binding site, exists primarily within the loop portion of this stem-loop (Figure lA-B). This loop
contains an uninterrupted sequence of five uracil and seven cytosine residues and is 25 residues
upstream of the 3' splice site and nine residues downstream of a consensus branch-point.
The affinities ofU2AF65 for regions of this intron were determined using an
electrophoretic mobility shift (gel shift) assay. U2AF65 bound to a 50 nucleotide sequence (cTNT
SOmer) containing the putative py-tract with an affinity (Kd) of 31 0 ± 30 nM (Figure 1C, see S.
Figure 1 for representative gel shifts). Truncated versions of this RNA that retained the putative
py-tract, but removed another run of pyrimidines nearer to the 3' splice site, showed an
unchanged binding affinity for U2AF65 (cTNT 32mer, Figure lB-C). Mutations that replaced the
putative py-tract nearly abolished U2AF65 binding (UUCG Loop, Figure lB-C). Based on its
location, the sequence of the region, and the binding data and the truncations, it is likely that this
region is indeed the py-tract and comprises the binding site of U2AF65 within this intron.
MBNLI and U2AF65 bind competitively to the 3' end ofintron 4
To determine whether MBNLl competes with U2AF65 for binding at this intronic site, a
UV cross-linking assay was used. While holding U2AF65 concentration constant, increasing the
concentration ofMBNLl strongly reduced U2AF65 cross-linking (Figure 2). If the two proteins
could bind to the RNA at the same time, it was expected that a ternary complex of higher
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molecular weight would be observed. However, since U2AF65 cross-linking was significantly
decreased and little or no apparent ternary complex was observed, it appears that MBNLl and
U2AF65 bind competitively to the cTNT 50mer-Wt sequence.
A mutated RNA (cTNT 50mer-4G, Figure 2) was used to determine if non-specific
binding ofMBNLl affected U2AF65 binding. In this RNA, four guanosine residues in the stem
were mutated that are required for MBNLl binding (84) and cross-linking (28), while U2AF65
binding and cross-linking remain intact. As expected, cross-linking of this RNA to U2AF65 was
not affected by MBNLl, showing that MBNLl specifically competes with U2AF65.
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MBNLl inhibits "A complex"formation on intron 4
The role ofU2AF65 is to define the 3' end of an intron and help recruit the U2 snRNP to
the branch-point (7, 8, 87), forming "A complex" (3, 4). If U2AF65 does not bind, recruitment of
the U2 snRNP to the branch-point is compromised (7, 8). We predicted that competition between
MBNLl and U2AF65 would inhibit formation of the A complex on this intron.
An RNA construct was made that contained human cTNT exon 5, together with 100
nucleotides of the 3' end of the RNA upstream of intron 4. Sequences from a constitutively
spliced intron from chicken troponin I (TNI) were placed upstream of that sequence (see Figure
3A for diagram). Radiolabeled RNA was incubated with HeLa nuclear extract, allowing splicing
complexes to form on the RNA substrate. A time course shows that this cTNT pre-mRNA forms
A complex well (Figure 3B). The ADML pre-mRNA substrate served as a positive control
because it forms A complex robustly (Figure 3B). In the absence of ATP, no complex band is
formed on the cTNT-Wt pre-mRNA, indicating that this is A complex (Figure 3C). At later time
points, larger complexes (B and C) are seen on the ADML pre-mRNA, but the cTNT pre-mRNAs
are not robust enough to form these complexes in vitro prior to RNA degradation.
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Figure 3. Time course and ATP dependence 0/complex/ormation assay. (A) Schematic of
cTNT pre-mRNA used in complex formation assay. (B) Time course of A complex formation
on cTNT-Wt, ADML and cTNT-4G pre-mRNAs. (C) Time course of A complex formation
on cTNT-Wt in the absence of ATP.
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The 10 minute time point was chosen to assay the affect of MBNL1 on A complex
formation because RNA degradation was minimal and complex formation was optimal on the
cTNT pre-mRNA (Figure 3B). Complex formation on the cTNT-Wt pre-mRNA was reduced by
nearly 2 fold with increasing concentrations ofMBNLl, while little effect was seen on ADML
pre-mRNA or on the mutant cTNT-4G pre-mRNA, (Figure 4A-B). This indicates that MBNLl
reduces the formation of A complex only on its specific pre-mRNA target, and does not perturb A
complex formation in general.
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mRJYA. (A) MBNLl reduces A complex formation strongly on the cTNT-Wt pre-mRNA, but
not on an ADML or cTNT-4G pre-mRNA. (B) Quantitation showing the affect ofMBNLl on
A complex formation on cTNT-Wt, cTNT-4G and ADML pre-mRNAs.
Stabilization ofthe stem-loop reduces U2AF65 binding affinity and represses exon 5
inclusion in vivo
We previously observed that mutations that increased the number of base-pairs in the
stem-loop repressed exon 5 inclusion, independently ofMBNLl (84). This led us to hypothesize
that these mutations might repress the inclusion of exon 5 by reducing the affinity of U2AF65 for
the py-tract, in a manner similar to the repression mechanism used by MBNL1. To investigate
this possibility we tested the affinity ofU2AF65 for the cTNT intron 4 py-tract using stem-loops
with increased stability.
A correlation was seen between the stability of the stem-loop and the binding affinity of
U2AF65, with stronger stems nearly abolishing U2AF65 binding (Figure 5A-B). The Stem
Strengthen (SS) mutation stabilized the stem by adding one base pair to each end of the stem,
increasing the Tm of the stem-loop by 5 °C, reduced U2AF65 binding ~10-fold (Figure 5A-B).
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The No Mismatch (NM) mutation increased the stability of the stem by 10 DC and reduced
U2AF65 binding to the point where a Ka value could not be determined (Figure 5A-B). It is
interesting that the mutation that more strongly stabilized the stem structure had a larger effect on
binding. This result suggests that U2AF65 binds the py-tract in a single-stranded region of this
RNA. As a negative control, a mutation (UUCG loop, UL) was made that removed the py-tract
from the loop to fully abolish U2AF65 binding (Figure 5A-B).
Furthermore, we found a strong correlation between U2AF65 binding affinity and exon 5
inclusion in vivo (Figure 5C-D). The NM, SS, UL mutations all showed minimal exon 5 inclusion
using an in vivo splicing assay. This repression was independent of MBNU, as co-expression of
expanded CUG repeats (which would sequester MBNL 1) had no affect on exon 5 inclusion for
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these mutations (Figure 5D). These results indicate that inclusion of exon 5 can be regulated
either by competition ofMBNLl with U2AF65 at the 3' end of the intron, or by the formation of
RNA secondary structures that reduce the affinity of U2AF65 for its binding site.
U2AF65 and MBNLl bind distinct RNA structures
To determine the effect ofMBNLl or U2AF65 binding on the stem-loop structure, a
fluorescence-based assay was used. The fluorescent adenosine analogue 2-amino purine (2-AP)
was used to replace a guanosine residue that forms a "wobble base pair" with a uracil residue near
the base of the stem (Figure 6A). 2-AP was chosen as a spectroscopic probe for this purpose
because its fluorescence is strongly quenched when it is in a base-paired structure (here with
uracil), while its fluorescence strongly increases when it is in a single-stranded environment. The
guanosine residue near the base of the stem was selected for replacement as no adenosine
residues were available in the stem and replacement of this position had no affect MBNLl or
U2AF65 binding or stem formation (data not shown).
Titration ofU2AF65 to the RNA increased the fluorescence of the probe nearly two-fold
(Figure 6B). In general, the fluorescence of a 2-AP probe has been shown to increase 2- to 3-fold
when 2-AP switches from a base-paired to a single-stranded environment (90). Therefore this
result suggests that U2AF65 binds this RNA in a single-stranded structure. U2AF65 was titrated
to a point where the RNA should be ~85% bound, based on the Kd determined from the gel shift
assay. A U2AF65 protein that contains four mutations which inhibit RNA binding (U2AF65-
Quad Mutant or QM (91)) had no effect on the fluorescence of the probe (Figure 6B).
In contrast to U2AF65, titration ofMBNLl (to a concentration at which 85% of the RNA
should be bound) had no significant effect on the fluorescence of the 2-AP probe (Figure 6C).
This result indicates that the stem structure remains intact upon MBNLl binding. However, a
recent crystal structure of two zinc fingers from MBNLl with a six nucleotide RNA suggests that
at least two of MBNLl 's zinc fingers bind RNA sequences in a single-stranded structure (92).
This crystal structure was only obtained with a minimal RNA sequence that was not long enough
to form a double-stranded structure, so it is unclear if a longer RNA sequence would be in a
different structure. It might be possible that MBNLl does bind the cTNT stem as single-stranded
RNA, but the protein quenches the 2-AP probe so that the fluorescence does not increase.
However, this is unlikely, as 2-AP probes have not been seen to be strongly quenched by direct
protein binding when compared to base stacking and base pairing in a stem (90, 93).
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The recent crystal structure argues that it is probable that MBNLl opens at least one or
two bases in the stem. However, this fluorescence data suggests that other portions of the stem
remain structured. We therefore conclude that at least a portion of the stem remains intact upon
MBNLl binding, while U2AF65 binds to a completely single-stranded structure.
A e ce e eCCe 82.2 0 U2AF65-W1
U U U U 2 "
U2AF65-oM 2
U e U e ~ i CI>u e U c g J + 6
g
u - G U - G ~ 1.8 ... ·····1 ~ 1.8b Ie e e c ~ I!!
G - U G - U g 1.6 ....1. g 1.6
C - G e - G i:i: 6 i:i:
U c u e ~ 1.4 .j .~ 1.4C - G e - G ~ (;ju - G U - 2AP
'lii 1.2 'lii 1.2G - e G - e a: Q .. L+ t a: .}u e u e ! t( A e A t5'( e 5'e e 0.8
Wildlype (WI) 2·Amino 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2Purine (2·AP) U2AF65 (J1M) MBNL1 (nM)
Figure 6. U2AF65 destabilizes the stem-loop upon binding, while MBNLl binds the stem-loop
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Discussion
MBNLl regulates the cTNT exon 5 through competition with U2AF65
To our knowledge, the competition ofMBNLl with U2AF65 represents the first example
of an alternative splicing factor that regulates splicing primarily through modulation of an RNA
structural element and not through direct occlusion of another splicing factor's binding site. The
competition ofMBNLl with U2AF65 does not constitute a novel mechanism, as other alternative
splicing factors have previously been shown to compete directly with U2AF65. The alternative
splicing factor Sex Lethal (Sxl) has been shown to compete with U2AF65 in the tra and msl-2
pre-mRNAs (88, 89), while the Poly-Pyrimidine Tract Binding Protein (PTB) has been observed
to compete with U2AF65 for sequences within the u- or ~-tropomyosinpre-mRNAs (94, 95).
Sxl and PTB both have binding specificities similar to that ofU2AF65, as all three
proteins primarily prefer long runs of single-stranded uracil residues (94). When competitively
binding with U2AF65, both Sxl and PTB are considered to occlude the U2AF65 binding site, and
sterically inhibit U2AF65 from accessing its binding site. On the other hand, MBNLl has a
42
different binding specificity from U2AF65, and binds adjacent sequences primarily outside of the
py-tract. We cannot rule out steric contributions to the competition between MBNLl and
U2AF65, but the fluorescence assay strongly suggests that these proteins bind this RNA in
different conformations (Figure 6). Both the differential binding sites ofMBNLl and U2AF65,
and the role that RNA secondary structure can play in modulating U2AF65 binding, suggest that
these splicing factors compete for recognition of the 3' end of intron 4 largely through binding
. mutually exclusive RNA structures (see Figure 7 for model).
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Figure 7. Model of regulation of cTNT exon 5 by MBNLl and RNA structure. (A) Initial
recognition of intron 4 by splicing factors. U2AF65 binds the intron in a single-stranded
structure, but U2AF65 is inhibited if it cannot destabilize the stem due to MBNLl binding or
mutations that stabilize the stem-loop. (B) U2 snRNP recruitment to all 3' splice sites were
U2AF65 is present. (C) Spliceosomal recruitment and splicing. (D) mRNA splice products.
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The novel role ofMBNLl in regulating alternative splicing by modulating RNA
secondary structure
It is well documented that RNA structural elements alone can regulate alternative
splicing. For instance, stable structures have been shown to inhibit VI snRNP binding to the 5'-
splice site following exon 7 of both the SMN1 and SMN2 pre-mRNAs (96). Other structural
elements that encompass exon 6B in chicken ~-tropomysin have been shown to inhibit binding of
all the V snRNPs, promoting the skipping of that exon (97). At present, it is unclear whether these
examples involve alternative splicing factors that regulate these RNA structures, as MBNLl
appears to regulate secondary structures within the cTNT pre-mRNA.
Other alternative splicing factors have been postulated to regulate RNA structural
elements, but there is no clear evidence to show that these factors modulate RNA structure in a
way that directly regulates alternative splicing. For example, the splicing factor hnRNP Al has
been shown to inhibit binding of splicing factors ASF/SF2 and SC35 when they regulate splicing
of the tat pre-mRNA from HIV-I (98). Binding ofhnRNP Al is thought to alter the secondary
structure of the pre-mRNA in a way that affects splicing (99), but this has not been demonstrated.
Similarly, ribosomal protein L32 from S. cerevisiae binds a structured RNA element near the 5'-
splice site of an intron within its own pre-mRNA, leading to intron retention (100). However, this
structured binding site allows for recruitment of the VI snRNP, showing that RNA structures do
not always inhibit binding of the V snRNPs (101). It is still unclear how L32 causes intron
retention if it does not inhibit binding of VI.
In regards to the competition between MENLl and V2AF65, it has been demonstrated
with a crystal structure that V2AF65 binds the py-tract in a single-stranded structure (102). In this
structure, seven uridine residues bind along two RNA recognition motifs ofV2AF65, leaving the
3' and 5' ends spatially far from each other. This crystal structure sheds light on why V2AF65
must bind the cTNT intron in a single-stranded form, as it is unlikely that the stem could form
with the loop in such an extended structure. At present, MBNLl is the first alternative splicing
factor that has been shown to regulate alternative splicing on the level of RNA structure. It is
likely that other examples will follow as it is becoming increasingly apparent that RNA structure
plays important roles in controlling pre-mRNA splicing.
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Materials and methods
Cloning andprotein purification. MBNLl and U2AF65 were purified as previously described
(84,91).
RNA synthesis, labeling andpurification. The RNA substrates used for the Complex formation
assay were transcribed with T7 polymerase, off linearized Puc19 plasmid. During transcription,
RNAs were radiolabeled using [a_32P]CTP. All other RNA substrates were ordered from IDT
DNA, and 5' end-labeled using [y_32p]ATP.
Cross-linking assay. RNA and proteins were incubated at room temperature for 10 minutes, then
on ice for 10 minutes, under the same conditions as used in the gel shift assay. Samples were
placed on a pre-chilled block and exposed to UV for 1 minute 20 seconds (l Joule / cm2), 3.5 cm
from the light source using a FB-UVXL-I000 lamp (Fisher Scientific). Samples were then
incubated in protein denaturing buffer for 2 minutes at 95°C and were resolved on a 10%
denaturing SDS-PAGE gel. Gels were then dried and autoradiographed.
Complex formation assay. HeLa nuclear extract was prepared (l03) and complex formation was
performed (5) as previously described.
Thermal melting curves. Tm values were obtained as previously described (84).
Gel shift assay. Final conditions for the RNA-U2AF65 binding experiments were 175 mM NaCl,
5 mM MgCh, 20 mM Tris (pH 7.5), 1.25 mM BME, 12.5% glycerol, 2 mg/ml BSA and 0.1
mg/ml Heparin. Prior to incubation, RNA substrates were snap annealed in 66 mM NaCl, 6.7
mM MgCh, and 27 mM Tris (pH 7.5). Protein was then added to the RNA, in a 10 f!L volume
and incubated for 10 minutes at room temp before 3-5 f!L were loaded on a pre-chilled 5%
acrylamide (37.5:1), 0.5x TB gel, and run for 1 hour at 175 volts, at 4°C. Gels were dried and
autoradiographed.
For binding curves, gels were quantified using ImageQuant (Molecular Dynamics). The
percent RNA bound was determined by taking the ratio of RNA:Protein complex to total RNA,
per lane. Binding curves were graphed and apparent Kd values were determined with
KaleidaGraph (Synergy) software using the following equation: y=((m2 + ml + mO)-((-m2 - ml -
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mOi-(4 x ml x mO))0.5/(2 x ml), where y=% RNA bound, m2= Ki, ml=total RNA concentration
and mO=protein concentration. This equation assumes a 1: 1 interaction between the RNA and
protein, which allows only an apparent Ki to be determined for RNAs containing more than one
binding site. To determine the standard error of the apparent Kis, 3-5 binding titrations were
performed with each substrate and the apparent Ki values determined for each titration separately.
Complex/ormation assay. HeLa nuclear extract was prepared (103) and complex formation was
performed (5) as previously described. In short, HeLa extract was added to a solution with RNA
and buffer and incubated at 30°C for the appropriate time point. The sample volume was 12 ~L,
and contained 25% HeLa extract, 55 mM KOAc, 30 mM KCl, 14.5 mM Hepes (pH 8.0), 10 %
glycerol, 0.12 mM EDTA (pH 8.0), 0.5 mM DTT, 3.2 mM MgCb, 0.5 mM ATP, 20 mM creatine
phosphate, 0.7 units / ~L of RNase Inhibitor (Ambion). After the appropriate time point, samples
were incubated with 4 ilL of heparin (4 mg/mL), and incubated at room temp for 2 minutes.
ADML and cTNT-wt samples were then loaded onto a pre-chilled 1.8% agarose gel (Ix TG), and
run at 75 volts for 1.5 hours, at 4°C, in a Ix TG solution. To better resolve A complex, cTNT-4G
samples had 80 mM KOAc, and were run on a 1.2% agarose gel (Ix TG), for 4.5 hours at 40
volts, 4°C. The gels were then fixed in 10% acetic acid, 10% methanol solution for 10 minutes.
Gels were dried, autoradiographed, and quantified using ImageQuant (Molecular Dynamics). To
determine the fold reduction, the percent of complex formed in the absence of MBNLl was
divided by the percent complex formed in the presence of MBNLl.
2-Amino purinefluorescence. RNA (Dharmacon RNA Technologies) was diluted to 1 11M
concentration in the binding buffer (I75 mM NaCl, 20 mM NaC!, 5 mM MgCb) and snap
annealed. All reactions were performed at room temperature, in the binding buffer, using an L-
formate Jobin-Yvon Horiba Fluoromax fluorimeter. A 3 mm wide Spectrosil microcell cuvette
(Stama Cells, Inc) was used. The 2-amino purine was excited at 312 nm, and spectra were
collected from 310 - 4~0 nm. The fluorimeter slits were 3 nm , with an integration time of 0.2
seconds. Spectra collected with buffer and protein were used to subtract out background. Three
spectra were collected and averaged for every titration point. To calculate relative fluorescence,
the value at 375 nm was used.
In vivo splicing. HeLa cell transfections, and RT-PCR was done as previously described (84).
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CHAPTER IV
PENTAMIDINE REVERSES THE SPLICING DEFECTS
ASSOCIATED WITH MYOTONIC DYSTROPHY
Contribution note: this chapter is under review for publication at PNAS. The other contributors
were Masayuki Nakamori, Catherine M Matthys, Charles A. Thornton and J. Andrew Berglund.
Masayuki Nakamori was co-first author with me on this publication and helped with experimental
design, performed many experiments and did a large amount ofdata analysis. Catherine M
Matthys performed many initial experiments. Charles A. Thornton helped with experimental
design and data analysis. J. Andrew Berglund helped with experimental design, data analysis and
manuscript preparation.
Introduction
Myotonic Dystrophy (DM) is an autosomal dominant genetic disorder that is
characterized by a variety of symptoms. There are two types of Myotonic Dystrophy, type 1
(DMl) and type 2 (DM2). DMI is linked to a (CTG)n repeat expansion in the 3' untranslated
region of the DMPK gene, while DM2 is linked to a (CCTG)n repeat expansion in intron 1 of the
ZNF9 gene. The current model is that the expanded repeats are toxic on the RNA level, where
either repeat can form a stable structured RNA that aberrantly interacts with proteins in the
nucleus (for review see (22, 85)).
One proposed molecular mechanism that may account for the disease symptoms is that,
upon transcriptions ofthe expansions, either the CUG or CCUG repeats sequester RNA binding
proteins from their normal cellular functions. The protein MBNLl (Muscleblind-like 1) has been
shown to bind both expanded CUG and CCUG repeats in vitro (38, 66, 75), and co-localize with
these expanded repeats in vivo (23, 51-54). MBNLl is an alternative splicing factor and its
sequestration leads to the mis-splicing of multiple pre-mRNAs in DM, which is thought to give
rise to many of the symptoms of the disease. In support of this model, it has been shown that the
disruption of the MBNLl gene or expression ofCUG repeats in mice causes symptoms and mis-
splicing similar to those seen in DM patients (46, 47, 62, 65). Furthermore, disease symptoms can
...--_-------------- -- -------
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be rescued and mis-splicing of many pre-mRNAs can be reversed in mice expressing CUG
repeats by over-expression of MBNLl (34).
Aside from the over-expression of MBNLl, another possible approach to overcoming the
sequestration of MENLl is to identify small molecules that specifically bind the CUG repeats and
would competitively release the sequestered MBNLl. As a step towards identifying a small
molecule therapeutic for DM, a small library of molecules known to bind structured nucleic acid
were screened for their ability to disrupt an MBNLl-CUG repeat interaction in vitro. Two
molecules were identified that strongly disrupted the complex in vitro. Further testing showed
that the molecule pentamidine was able to rescue mis-splicing of four tested pre-mRNAs in both
cell culture and a mouse model of DMI.
Results
Identification ofsmall molecules that disrupt an MBNL1-CUG repeat complex in vitro
Twenty-six small molecules that are known to bind structured nucleic acid (Table 1) were
screened to identify compounds that would disrupt a protein-RNA complex using a previously
characterized MBNLl-CUG repeat gel shift assay (Figure lA) (84). The CUG RNA (CUG4) used
in this screen contains four repeats, which were stabilized into a stem-loop structure by using the
ultra stable UUCG loop (Figure lA). The molecule that most effectively disrupted the complex
was pentamidine, which competed with MBNLl and disrupted the protein-RNA complex with an
ICso of 58 ± 5 1!M (Figures 1B-D). Neomycin B was the next best molecule with an ICso of280
(Figures IB-D). The small molecules ethidium bromide and thiazole orange also disrupted the
MBNLl-CUG4 complex with an ICso in the 200-300 1!M range (Table 1). However due to
toxicity issues with ethidium bromide and thiazole orange, only pentamidine and neomycin B
were chosen for further study to determine their ability to disrupt the MBNLl-CUG repeat
interaction in vivo.
Pentamidine rescues mis-splicing in BeLa cells oftwo pre-mRNAs mis-regulated in
DM
To determine if either small molecule could rescue mis-splicing in cells, we investigated the
alternative splicing of the insulin receptor (IR) and cardiac troponin T (cTNT) minigenes in HeLa
cells, in the presence or absence of expanded CUG repeats. Both of these pre-mRNAs are mis-
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Table 1. List of26 screened small molecules. Molecules are divided into groups based on
structure. Listed are the roviders and roduct order number.
M
Aminoglycosides
Actinomycin D
(117,
118)
Intercalates DNA and A-fonn RNAD9542Sigma
Sigma A2024 Binds rRNA in eukaryotes and prokaryotes (106,
107)
Sigma GSO!3 Binds A site in bacterialribQSome (108)
Sigma 91955 Binds RNA and DNA (109)
. (110•
. ,111)
181 Sci IB02120 Binds A site in bacterial ribosome (110,
111)
(106,
110)
280 ± 40 Sigma Nl876 Binds A site in bacterial ribosome (110,
111)
1
-1,600 MPBio 210360010 Binds DNA with alternating purines and (112)
pyrimidines
(106•
. 110)
/ Sigma S6501 Binds bacterial 16 S rRNA (113)
/ IBI Sci.' IB02200 Binds Aand P site in bacterial ribosoine • ·(114)
/ Sigma T1783 Binds A site in bacterial ribosome (111)
-1,000 Sigma B2261 Binds minor groove ofDNA, in AT rich (115)
regions
Ribostamycin Sulfate
Streptomycin Sulfate
Tetracyclin Hydrochloride
Tobramycin Sulfate
Dyes
Bisbenzimidine Hoechst
No. 33342
Bisbenzimidine Hoec
No. 33258
DAPI
Apramycin Sulfate
Lividomyc'
Kanamycin Sulfate
Paromomycin Sulfate
Geneticin Disulfate
Genistein
Neomycin B
Proflavine Hydrochloride
(122)
(124-
127)
(128)
(129,
130)
Binds tRNA, and A-fonn DNA.
Intercalates DNA with high affinity
Binds structured RNA. Binds AT rich DNA
in the minor groove. Inhibits splicing of
group I and II introns. Modifies Ubiquitin.
P0547
A38401
IB02040
Sigma
Sigma
IBI Sci
Sigmll' ..$292.6. ~.' .~ ...;e.... BindstRNA.:. '.' .
Sigma S3256
58 ±5
Misc.
Ampicillin
Berenil
SpefIIlidine .
Spermine
Thiazole Orange
Amiiles
9-Aminoacridine
Hydrochloride Hydrate
L-Ar ide
Dihyd ride
Pentamidine Isethionate
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Figure 1. Screen for small molecules that disrupt an MBNLI-CUG complex in vitro.
(A) Representative gel of MBNLl complexed with the CUG4 construct. (B)
Representative gels of pentamidine and neomycin B disrupting the MBNLl-CUG4
complex, and two small molecules that had no effect, kanamycin and paromomycin. The
MBNLl concentration in each lane is 500 nM. (C) Graph depicting competition of
pentamidine, neomycin B, kanamycin and paromomycin with MBNLl. (D) Molecular
structure of pentamidine and neomycin B.
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spliced in DM patients (25, 26, 28, 56, 60, 62, 84, 131). MBNLl represses inclusion of exon 5 in
the cTNT pre-mRNA and binds directly upstream of exon 5 (28, 84). MBNLl positively
regulates the inclusion of exon 11 of the IR pre-mRNA, but it is unknown if MBNLl directly
binds this pre-mRNA (25, 26, 28, 49, 56). It has been shown that the over-expression of 960
interrupted CUG repeats sequesters MBNLl to foci containing the CUG repeats, and ablates the
regulation of multiple pre-mRNAs by MBNLl, including the regulation of these two minigene.
pre-mRNAs (25, 28, 49, 84). A plasmid containing these 960 repeats can be transfected into
HeLa cells, thus providing a cell based model for studying the splicing defects of DM.
We observed that the addition of pentamidine was able to rescue the mis-splicing of both
the cTNT and IR minigene pre-mRNAs caused by the expression of the expanded CUG repeats
(Figure 2A-C). For the IR pre-mRNA, the basal level of inclusion of exon 11 in HeLa cells is 97
± 1%, while co-transfection with the CUG repeat plasmid reduces inclusion to 73 ± 1%. The mis-
splicing was mostly rescued at 25 IlM pentamidine, returning exon 11 inclusion to 92 ± 3%
(Figure 2A-B). Exon 11 levels were fully rescued to normal levels by 50 IlM pentamidine.
We next tested if mis-splicing of the cTNT pre-mRNA could be rescued by pentamidine
(Figure 2C). Exon 5 inclusion was seen to have a basal level of inclusion of75 ± 4% in HeLa
cells, while co-transfection of CUG repeats raised it to 95 ± 2%. Pentamidine also rescued this
mis-splicing, though higher concentrations were required for rescue compared to the IR substrate.
Inclusion of the cTNT exon 5 to normal levels was observed at 75 IlM pentamidine, while 50 IlM
pentamidine showed a partial rescue, and 25 IlM pentamidine had no effect (Figure 2C).
Unexpectedly, in the absence of CUG repeats, pentamidine was observed to reduce the inclusion
of exon 5. We recently reported that MBNLI competes with the essential splicing factor U2AF65
at the 3' end of intron 4 to block inclusion of the cTNT exon 5 (132). MBNLl binds a stem-loop
in this area and this interaction blocks U2AF65 binding in this region of the intron because
U2AF65's single-stranded binding site is sequestered in the stem-loop. We hypothesized that
pentamidine was binding this stem-loop and blocking U2AF65 binding, through a mechanism
similar to MBNLl inhibition. Supporting this model we found that pentamidine competed with
U2AF65 for binding to the 3' end of the intron (Figure 3). This result suggests that for the cTNT
pre-mRNA both MBNLl and pentamidine bind the same site to additively repress exon 5
inclusion in the absence of the CUG repeats, thus explaining the low levels of exon 5 inclusion in
the absence of CUG repeats (Figure 2C). However, as the effect is less penetrant in the presence
of CUG repeats, it appears that pentamidine is titrated to these repeats when they are present.
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Since pentamidine was found to regulate cTNT exon 5 levels of inclusion in the absence
of CUG repeats, we wanted to investigate if pentamidine might generally affect splicing of other
RNAs. We first tested its affect on the splicing of a highly expressed pre-mRNA from another
minigene, as the previous pre-mRNAs tested were also from minigenes. The splicing of the
PLEKHH2 pre-mRNA (that contains exons 20-22, all of which are constitutively included when
endogenously expressed) was tested and found to be unaffected by the addition of either
pentamidine or the expression of CUG repeats (Figure 2D). We next determined if pentamidine
affected the alternative splicing of endogenous pre-mRNAs in HeLa cells. None of the four
alternatively spliced exons tested were affected by either the expression of the CUG repeats or the
addition of75 fLM pentamidine (Figure 2E). These results suggest that pentamidine does not
globally affect either constitutive or alternative splicing, but only a subset ofpre-mRNAs, which
are MBNLl dependent. Furthermore, it suggests that pentamidine does not affect either highly
expressed pre-mRNAs (such as the PLEKHH2, which was expressed from a plasmid with a
strong promoter), or the four endogenously expressed gene, which are likely to be expressed at
much lower levels. Finally, it should be noted that transcript levels appeared relatively unchanged
upon the addition ofpentamidine for any of these pre-mRNAs. This indicates that pentamidine
does not globally affect transcription or RNA turnover at the concentrations tested.
To determine if neomycin B was able to rescue the mis-splicing induced by CUG repeat
expression, it was also tested in the splicing assay. Neomycin B did not alter the splicing of either
the cTNT or IR pre-mRNAs (Fig 4). For the cTNT pre-mRNA, concentrations up to 200 IlM
neomycin B were tested (Fig 4A), for the IR pre-mRNA 500 IlM was tested (Fig 4B). These
results indicate that neomycin B does not specifically bind the CUG repeats in this DMI cell
model, suggesting that neomycin B is likely binding other substrates in the cell.
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Figure 2. Pentamidine rescues mis-splicing ofMBNLI dependent pre-mRNAs in HeLa
cells. (A) Representative RT-PCR data for the IR minigene pre-mRNA (exons 10-12)
under pentamidine treatment. (B) Bar graph representation of pentamidine rescuing mis-
splicing of IR exon 11. (C) Bar graph representation of pentamidine rescuing mis-
splicing of cTNT exon 5. (D) Bar graph representation of splicing of the PLEKHH2
minigene (exons 20-22) in the presence of either CUG repeats or pentamidine. (E) Bar
graph representation of splicing of four endogenously expressed genes in HeLa that are
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Pentamidine reduces CUG repeatfociformation and relieves MBNLI sequestration in
HeLa cells
To directly visualize pentamidine's effect on MBNLl sequestration, CUG foci formation
was investigated in the presence and absence of the small molecule. Using an anti-MBNLl
antibody, MBNLllocalizes to the nucleus of HeLa cells, without CUG repeats or pentamidine
present (Figure 5A-D). Upon transfection with the CUG960 plasmid, characteristic RNA
ribonuclear foci were formed, which sequestered nearly all of the MBNLl (Figure 5E-H). Upon
the addition of75 JlM pentamidine, we observed that foci formation was decreased. We scored
CUG transfected cells, with or without pentamidine, for foci formation. Cells were scored as
either having foci or having no foci. Foci formation was reduced by 21 % in the pentamidine
treated cells. While this is not a full reduction, a chi test gave a P value of 0.004, showing the
difference between treated and untreated cells was significant. In cells treated with pentamidine
where foci were eliminated, MBNLl was found to be diffuse throughout the nucleus (Figure 51-
L). This assay was also performed in HEK293 cells, which contain higher levels of endogenous
MBNLl. In this cell line, foci formation was reduced 28% by treatment with 50 JlM pentamidine.
A chi test gave a P value of 0.5 x 10-4°, showing the difference between treated and untreated
cells was also significant in this cell line.
Pentamidine partially rescues mis-splicing oftwo pre-mRNAs in a DMI mouse model
We tested pentamidine's ability to rescue mis-splicing in a mouse model (HSALR) for
DMI in which 250 CUG repeats are expressed under an actin promoter (45). Pentamidine was
administered by intraperitoneal injection in two dosage regimens, and mis-splicing of the
chloride-l (Clc-l) and Sercal pre-mRNAs was assayed. Both of these pre-mRNAs are mis-
splicing in DM; MBNLl represses inclusion of exon 7a in the Clc-l mRNA and enhances
inclusion of exon 22 in the Sercal mRNA (24, 85, 133).
Adult mice normally have a Clc-l exon 7a inclusion of 6 ± 1%, while the HSALR line has
a level of 54 ± 6%. Pentamidine treatment at a lower dosage (25 mg/kg twice at day) partially
rescued inclusion to 37 ± 3%, while a higher dosage regimen (40 mg/kg once a day) rescued
splicing to 34 ± 4% exclusion (Figure 6A, C). When comparing the low dosage treatment to
injection of only saline, the P value was <0.003 when using a Mann-Whitney U-test. The P value
for the high dosage treatment was <0.001. The number of mice used for each trial is noted in
Figure 6C-D.
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Figure 5. Pentamidine re(luces tlle/ormatio11 ofCUG ribo11uclearfoci and relieves
MBNLJ sequestration. (A-D) Untreated HeLa cells, with MBNLl localizing to the
nucleus. (E-H) Transfection with CUG9r>O gives rise to ribonuclear foci, characteristic of
OM, with MBNLI co-localizes with the CUG repeats at the foci. (I-L) [n cells where
pentamidine (75 flM) reduced formation of the foci, MBNLl sequestration is fully
relieved.
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Inclusion of the Serca1 exon 22 is normally 99.7 ± 0.1 % in adult mice, while HSALR
mice have drastically lower levels of 17 ± 4%. Lower dosage pentamidine treatment minimally
rescued exon 22 inclusion to 22 ± 2%, while the higher dosage treatment more significantly
rescued exon 22 inclusion to 40 ± 4% (Figure 6B, D). The P value for the lower dosage treatment
regimen was < 0.01, while the higher dosage regimen had a P value that was < 0.001.
Further increases to the dosage regimens had substantial toxicity in the mice. An increase
to 30 mg/kg twice daily was lethal, while dosages at or less than 25 mg/kg twice a day, or
40mg/kg once a day were not. It is likely that higher levels of pentamidine could indeed further
reverse the mis-splicing of these transcripts. However, this full rescue may not be achievable with
pentamidine in HSALR mice, due to the toxicity. Nonetheless, the partial rescue that was observed
was statistically significant and strongly indicates that a small molecule can indeed work in a
mammalian DM model to reverse mis-splicing.
Figure 6. Pentamidine partially
rescues mis-splicing oftwo pre-
mRNAs in a DMl mouse
model.
(A) RT-PCR analysis showing a
dose dependent partial rescue of
mis-splicing ofClc-1 exon 7a. (B)
RT-PCR of partial dose dependent
rescue ofthe mis-splicing of Serca1
exon 22. (C) Bar graph
representation of parti al rescue of
Clc-1 exon 7a splicing. The
number of mice used for each
sample is denoted as N. Using a
Mann-Whitney U-test, the
significance of rescue for both the
low compared to the saline
treatment had a P value < 0.003,
while the high dose treatment had a
P value < 0.001. (D) Bar graph
representation of partial rescue of
Serca1 exon 21 splicing. The low
dosage had a P value < 0.01, while
the high dosage had a P value <
0.001.
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Discussion
Small molecules that hind nucleic acids as therapeutic agents for disease treatment
Many small molecules have been shown to bind and affect nucleic acid structure and
function. Examples include aminoglycosides binding to specific sites in ribosomal RNA to inhibit
various steps of translation or cisplatin cross-linking DNA to inhibit transcription and replication
(134-136). Dervan and colleagues have been quite successful in designing molecules that target
specific sequences in DNA (137), but that technology doesn't exist for targeting specific RNA
structures and sequences. Efforts are currently underway to understand the rules of small
molecule-RNA interactions (138, 139). To determine if CUG repeats could be targeted by small
molecules we screened a small library of known nucleic acid binding molecules and found that
pentamidine and neomycin B bound CUG repeats and could displace MBNLl in vitro. This
limited screen of small molecules, plus recent screens by Gareiss and colleagues and
Pushechnikov and colleagues with short peptides and peptoids (140, 141), clearly demonstrates
that CUG repeats can be targeted and that high throughput screens with large libraries of small
molecules will almost certainly produce many additional lead compounds other than pentamidine
for further studies.
Pentamidine is currently used to treat Pneumocystis carinii infections (pneumonia) in
AIDS (Acquired Immuno-Deficiency Syndrome) patients and to treat patients with
Trypanosomiasis and Leishmaniasis infections (142, 143). Although pentamidine has been shown
to bind to both DNA and RNA, the mechanism of its antifungal activity is unknown. Pentamidine
may inhibit P. carinii growth by inhibiting the splicing of essential group I introns in this
organism (124, 126), although more recently pentamidine has also been shown to inhibit
translation (144). It has also been proposed that pentamidine blocks DNA replication (143), as a
structure of pentamidine with DNA shows that it binds DNA in the minor groove (127).
Therefore it is likely that pentamidine interacts with many different nucleic acid targets within
cells. Our results suggest pentamidine can, at least, partially target CUG repeats and release
MBNLl. It is interesting to note that we previously showed that CUG repeats form an A-form
structure, despite the U-U mismatches (40), although the minor grooves of A-form and B-form
nucleic acid differ in architecture it is tempting to speculate that pentamidine binds the minor
groove of the A-form CUG repeats.
The results with pentamidine are in contrast to neomycin B which also disrupted the
MBNLl-CUG repeat interaction in vitro (Figure 1), but did not rescue mis-splicing of any of the
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tested targets (Figure 4). Both pentamidine and neomycin B are known to bind many different
nucleic targets, but only pentamidine displayed the ability to reverse the mis-splicing offour
different pre-mRNAs affected by CUG repeats. These results suggest that pentamidine sufficient
specificity for CUG repeats to have an effect in these assays, specificity that neomycin B
apparently lacks.
The efficacy ofpentamidine as a potential therapeutic for DM
The window of efficacy for pentamidine treatment in the DM1 cell culture and mouse
model is narrow. Substantial cell death is observed in BeLa cells with pentamidine treatments of
100 to 125 flM. Raising the concentration of pentamidine for the mice treatments is also
problematic because pentamidine dosages of 30 mg/kg twice a day are lethal to the mice, while
40 mg/kg twice once a day only partially relieves mis-splicing of the two tested pre-mRNAs
(Figure 6). To overcome this toxicity, modifications to pentamidine will be performed to enhance
the affinity and specificity of pentamidine for CUG repeats, thus allowing for a lower dosage
treatment. The length of the carbon linker between the aromatic groups will be optimized for
binding to the CUG repeats and functional groups containing B-bond donors and acceptors will
be added to the molecule in an attempt to create new specific interactions with the CUG repeats.
Another approach to improve pentamidine's affinity and specificity for CUG repeats will be to
oligomerize pentamidine to obtain multivalent binding to the repeating CUGs. A multivalent
strategy was recently used to obtain ligands that bind CCUG repeats with nanomolar affinity
(145), supporting the idea that covalent linkage of multiple pentamidines should result in
compounds with significantly better affinities to CUG repeats.
Previous potential therapeutic approaches for DM1 have ranged from over-expression of
MBNU, RNA interference against the CUG repeats, to targeted degradation of the mutant
DMPK transcript with an RNA ribozyme (34-37). We have now demonstrated that releasing
MBNU from the CUG repeats with a small molecule is another valid approach that should be
considered for treating DM1.
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Material and methods
MBNLl cloning andpurification. MBNLl was PCR amplified and was cloned into GST fusion
vector pGEX-6P-l (Amersham), using DNA (MBNLl isoform with amino acids 1-382) provided
by Maury Swanson (28). The MBNLl (1-260) construct used in this study was cloned using
BamHI and Not! restriction sites. Using BL21-Star expression cells (Invitrogen), protein
expression was induced with 0.25 mM IPTG at an OD6oo ~ 0.5-1, for 3-4 hours at 3rC. Cells
were lysed in 30 mL of buffer (500 mM NaCI, 25 mM Tris pH 7.5, 10 mM ~-Mercaptoethanol
(BME) and 5% glycerol) using 1 mg/ml oflysozyme followed by sonication (3 x 30 seconds).
Cell extract was centrifuged for 15 minutes at 17,000 rpm, and lysate which contained GST-
MBNLl was collected. GST-MBNLl was bound to GST affinity beads for 30 minutes at 4°C.
Beads were washed 5 times with buffer (1M NaCI, 25 mM Tris pH 7.5 and 5mM BME); MBNLl
was cleaved from the affinity tag with Precision Protease (Amersham) and collected from the
beads. The protein was then run over an anion exchange (Q) column. Co-purifying contaminants
bind the column, but MBNLl does not. MBNLl was collected in the column flow through,
concentrated and dialyzed into storage buffer (30% glycerol, 300 mM NaCI, 20 mM Tris pH 7.5,
5 mM BME) and stored at -80°C. Aliquots were removed from -80°C and temporarily placed in
-20 °C until used for an experiment.
RNA labeling andpurification. All RNA substrates that were radiolabeled were ordered from
IDT DNA, and 5' end-labeled using [y)2p]ATP and all RNAs were purified on an 8% denaturing
acrylamide gel.
Gel shift assay. The final concentration in the reaction was 125 mM NaCI, 5 mM MgCb, 20 mM
Tris (pH 7.5), 7.5% glycerol, 2 mg/ml BSA and 0.1 mg/ml Heparin. Prior to mixture with protein,
RNA substrates were snap annealed (95°C for 1 min then directly on ice for 20 min) in 66 mM
NaCI, 6.7 mM MgCb, and 27 mM Tris (pH 7.5). Protein and the small molecule were then added
to the RNA. The binding reaction was in 10 ~L volume and was incubated for 10 min at room
temperature (RT) before 2-4~L were loaded on a pre-chilled gel. RNA and RNA-protein
complexes were separated on 3% acrylamide (37.5:1),0.3% agarose (low melting point), 0.5x
Tris-Borate (TB) gels that were run for 2-3 hours at 4°C, 25-50 volts. For U2AF65, a 6%
acrylamide (37.5: 1), 0.5x TB was used and run at 175 volts, 4 °C for 2 hours. Gels were dried and
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autoradiographed. All small molecules were dissolved in water, ethanol, or ethanollDMSO
(50:50) according to manufacture's guidance for solubility.
For binding curves, the apparent Kd values were determined as previously described (84).
In brief, gels were quantified using ImageQuant (Molecular Dynamics). The percent RNA bound
was determined by taking the ratio ofRNA:Protein complex to total RNA, per lane. Binding
curves were graphed and apparent~ values were determined with KaleidaGraph (Synergy)
software using the following Equation 1, where y=% bound, m2= ~, ml =total RNA
concentration and mO=protein concentration.
Equation 1: y = ((mo+ mI + m2) - ~(-mO-mI- m2)2 - (4 x mOx mI))j(2 x mI)
This equation assumes a 1: 1 interaction between the RNA and protein, which allows only
an apparent Kd to be determined if the RNA contains more than one binding site. To determine
the standard error of the apparent dissociation constants, 3-5 binding titrations were performed
with each substrate and the apparent~ values determined for each titration separately, prior to
averaging. The error bars on the binding curve were obtained by averaging the individual titration
points and calculating the standard deviation. Data points greater than two standard deviations
from the average were discarded, with at least three data points remaining for standard deviation
analysis.
To determine the ICso, Equation 2 was used, where mO= small molecule concentration,
m1= ICso, m2= Hill coefficient, and m3= fraction MBNU bound without small molecule present.
Equation 2: Y = m3 /[1+ (mO /m1t2]
In vivo splicing. Wild-type cTNT and DMPK-CUG96o minigenes were obtained from the lab of
Thomas Cooper (Baylor College of Medicine). The insulin receptor minigene was obtained from
the lab of Nicholas Webster (UCSD). The PLEKBH2 minigene was cloned from BeLa genomic
DNA. Exon naming was determined using release 18 of the UCSC genome browser.
BeLa cells were grown in monolayers in DMEM with GLUTAMAX (GIBCO) and
supplemented with 10% fetal bovine serum (GIBCO). Approximately 2.0 (± 0.2) xl0s cells were
plated in 6 well plates and transfected 18-20 hours later at 70-90% confluency. 1 ug of plasmid
was transfected into each well of cells, using 5 uL of Lipofectin2000 (Invtitrogen) according to
the manufacturer's protocols. For co-transfection, 1 ug of total plasmid was transfected, at 500 ng
of each construct. The remainder of total plasmid was empty vector, if needed. Cells were
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incubated in low growth OPTI-mem media (GIBCO) for four hours, then cells were washed with
Ix PBS, and placed in normal DMEM growth media. Pentamidine was added at this point, if
being assayed.
After 20-24 hours, cells were washed with Ix PBS and harvested using triplE reagent
(GIBCO). Following harvesting, cells were either stored temporarily at -80°C, or RNA was
immediately isolated using an RNeasy kit (QIAGEN). Isolated RNA (500 ng) was DNased with
RQI DNase (Promega) according to manufacture's protocol. DNased RNA (100 ng) was reverse
transcribed with Superscript II and a gene specific reverse primer according to manufacturer's
protocols. DNA from the RT reaction (30 ng) was subjected to 22-25 rounds ofPCR
amplification using specific primers spiked with a kinased forward primer. The linear range for
PCR was determined for the cTNT and the IR construct and found to be between 20-26 cycles.
The linear range for PCR for PLEKH2 was determined to be 25-27 cycles. The resulting PCR
products were run on a 6% (19:1) poly-acrylamide denaturing gel at 6W for 2 hours. The gel was
subsequently autoradiographed and quantitation of the radioactive bands was performed using
ImageQuant software.
For testing of the endogenously expressed genes, cells were transfected with an empty
pcDNA3 vector, with or without the construct containing the CUG expansions. A total of 1 ~g of
plasmid was transfected. Cells were then treated with or without pentamidine. Cells and RNA
were harvested as normal. All the isolated RNA was DNased, using RQl DNase. Following
DNase, RNA was ethanol precipitated and re-suspended in approximately 10-20 ~L of water.
RNA was standardized to 300 ng/~L and cDNA was made. Both random hexamers and oligoDT
were used for the RT reaction. Random hexamers and oligoDT were used at a concentration of95
ng and 600ng per 3,600 ng of RNA, respectively. For the RT reaction, DNased RNA, primers and
0.8 mM dNTPs were incubated at 70°C for 5 minutes, then placed on ice for 5 minutes. RNA
was then reverse transcribed with Super Script II, according to the manufacture's protocol. DNA
(600 ng of RNA, or 2~L) was then used as a template for PCR, with gene specific primers, with a
Tm of 55°C, and 30 cycles. Samples were then run on a 2-3% agarose gel and imaged with
ethidium bromide. ImageQuant was used to quantify the gel.
The following primer pairs were used. For the cTNT minigene, the forward primer was
5'GTT CAC AAC CAT CTA AAG CAA GAT G, and the reverse primer was 5'GTT GCA TGG
CTG GTG CAG G. For the IR minigene, the forward primer was 5' GTA CAA GCT TGA ATG
CTG CTC CTG TCC AAG ACA G, and the reverse primer was 5' GCC CTC GAG CGT GGG
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CAC GCT GGT C. The underlined sections are for cloning purposes. For the PLEKHH2
minigene, the forward primer was 5' CGG GGT ACC AAA TGC TGC AGT TGA CTC TCC,
and the reverse primer was 5' CCG CTC GAG CCA TTC ATG AAG TGC ACA GG. For the
endogenous genes, the following primer pairs were used. CAMKK2 forward primer was 5'
CCTGGTGAAGACCATGATACG, and the reverse primer was 5'
GGCCCAGCAACTTTCCAC, with PCR products sizes 247 and 204 bases (for inclusion of
exclusion of alternative exon). For DLG1, the forward primer was 5'
AGCCCGATTAAAAACAGTGAAA, and the reverse primer was 5'
CGTATTCTTCTTGACCACGGTA, with possible PCR product sizes of 209, 179 and 143 bases
(with the largest product size being denoted as inclusion, and the smallest as exclusion). For
TTC8 the forward primer was 5' AGCTATTTTAGGCGCAGGAAGT, and the reverse primer
was 5' TTTTCATCCAGCATCATTTCTG, with PCR products of209 and 179 bases. For VTIl,
the forward primer was 5' GATCGCCTACAGTGACGAAGTA, and the reverse primer was 5'
TCCACTGCTATTTGGTATCCAG, with PCR products sizes of 168 and 147 bases.
Microscopy. HeLa or HEK294 cells were plated in 6 well plates onto coverslips. Cells were
transfected with the normal protocol. For transfection, 500 ng of CUG960 plasmid were
transfected for each experiment. A total of 1 flg of plasmid were transfected, with the additional
amount being empty pcDNA3 vector. After transfection, pentamidine was added and the cells
were fixed 16 hours later.
Cells were fixed for 15 min at RT with 4% PFA and washed 5 times for 10 min in Ix
PBS at RT. Cells were stored in 4° C, ifnot probed immediately. For the FISH (fluorescence in
situ hybridization) procedure, cells were permeabilized with 0.5% triton x-100, in Ix PBS at RT
for 5 min. Cells were pre-washed with 30% formamide, 2x SSC for 10 min at RT. Cells were
then probed for 2 hours at 37°C, with a 1 ng/flL of Cy3 CAG IO probe (IDT, IA) in 30%
formamide, 2x SSC, 2flg/mL BSA, 66 flg/mL yeast tRNA, 2mM vanadyl complex. Cells were
then washed for 30 min in 30% formamide, 2x SSC at 42° C, then with Ix SSC for 30 min at RT.
Cells were next washed twice in Ix PBS, 10 min at RT, and then probed overnight, at 4 ° C with
anti-MBNLl antibody (l :5000 dilution, A2764 antibody) in Ix PBS. Cells were washed two
times, for 10 mins at RT with Ix PBS. Next, cells were incubated with goat anti-rabbit Alexa 488
(l :500 dilution) for two hours at RT. Cells were washed two times, for 10 mins at RT with Ix
PBS and then mounted onto glass slides using hardest mounting media that contains DAPI
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(Vectashield, Peterborough England). Cells were imaged on an Olympus Fluoview FVI000 with
a Bx61 scope (Center Valley, PA). The number of cells scored was 254 for the CVG960
transfection, and 193 cells were scored when cells were treated with pentamidine (75 I..lM). A chi
test with two degrees of freedom was performed using Excel (Microsoft).
Treatment in mice. Mouse handling and experimental procedures were conducted in accordance
with the Association for Assessment and Accreditation of Laboratory Animal Care. HSALR
transgenic mice in line 20b were previously described (45). These mice express human skeletal
actin mRNA with ~250 CVG repeats in the 3' VTR. Age- and gender-matched HSALR mice were
injected intraperitoneally with pentamidine or saline alone. For a low-dosage regimen, 25 mg/kg
of pentamidine were administrated twice daily for 5 days. For a higher-dosage regimen, 40 mg/kg
of pentamidine was injected once daily for 7 days. Mice were sacrificed one day after the last
injection, and vastus muscle was obtained for splicing analysis. RNA extraction and eDNA
preparation were performed as described previously (55). PCR amplification was carried out for
22-24 cycles with the following primer pairs:
Clcl forward: 5'-TGAAGGAATACCTCACACTCAAGG-3',
and reverse: 5'-CACGGAACACAAAGGCACTG-3'.
Sercal forward: 5'-GCTCATGGTCCTCAAGATCTCAC-3',
and reverse: 5' -GGGTCAGTGCCTCAGCTTTG-3'. The PCR products were analyzed on
agarose gels and scanned with a laser fluorimager (Typhoon, GE Healthcare). Differences
between two groups were evaluated by the Mann-Whitney V-test.
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CHAPTER V
CONCLUSIONS
The RNA binding specificity of MBNLI for CUG and CCUG repeats
Prior to my dissertation research, very little was known ofMBNLl 's binding specificity.
It was clear that MBNLl co-localized with CUG and CCUG repeats, and could be pulled down
from cellular extract by CUG repeats. Cross-linking data also indicated that it might directly bind
to the cTNT pre-mRNA to directly regulate pre-mRNA splicing. However, it was unclear what
MBNLl 's RNA binding specificity and affinity was for various targets, and how strongly it
bound the CUG/CCUG expansions in comparison to any endogenous pre-mRNAs that it might
directly regulate.
One ofthe first steps that I made towards dissecting MBNLl 's binding specificity was
the mutational study ofCUG repeats. Analysis of RNA substrates in which the CUG repeat tract
sequences are modified in various ways (Chapter II, Figure 2) clearly shows the preference of
MBNLl for pyrimidine-pyrimidine mismatches as well as the Watson-Crick base pairs in their
particular positions. The lack of significantly higher affinity binding to longer CUG repeats
suggests that MBNLl does not bind in a highly cooperative manner to CUG repeats. These
results suggest this version ofMBNLl recognizes the many binding sites on long CUG repeats as
independent binding sites. Both the specific recognition and structural distortion of CUG repeats
are likely playing a role in MBNLl binding. The distortion of CUG repeats is supported by the
decrease in CD signal and the peak shift upon MBNLl binding to the CUG repeats and the cTNT
SOmer (Chapter II, Figure 4).
I next found that MBNLl binds CCUG repeats with approximately 2-fold stronger
affinity in both structural conformations (Chapter II, Figure 2-3) compared to the CUG repeats.
These results are surprising because patients with DM2 tend to have more CCUG repeats
compared to DMI patients with CUG repeats (75). Additionally, the ZNF9 pre-mRNA containing
the CCUG repeats appears to be expressed at similar or even higher levels than the DMPK pre-
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mRNA (50, 76). Yet, the symptoms ofDM2 patients are less serious than those ofDMl patients
(77). This supports the model that the expanded CUG repeats, unlike the CCUG repeats, are
affecting transcription or other processes in the cell and create another layer of mis-regulation in
DMI compared to DM2 (21). Further studies are required to understand how DMI and DM2
differ, as my results suggest it is not as simple as just the sequestration ofMBNLl to the RNA
repeat expansions.
The RNA binding specificity of MBNLI for the cTNT pre-mRNA
My observation that MBNLl binds short CUG and CCUG stem-loops prompted me to
consider that MBNLI might recognize a short stem-loop within the cTNT pre-mRNAs as well. I
chose to study the cTNT intron 4 because it was the only available pre-mRNA substrate with a
putative binding site (28). The combination ofUV melting of the cTNT SOmer RNA (Chapter II,
Figure 4E), circular dichroism information in the absence and presence ofMBNLl (Chapter II,
Figure 4F), structure probing of the cTNT 32mer (Chapter II, Figure 6A-B) and fluorescence
studies (Chapter III, Figure 6C) show that MBNLl binds this RNA in a stem-loop structure
which appears to be partially A-form. This proposed helix has some similarities to the CUG and
CCUG helices in that one of the pyrimidine-pyrimidine mismatches is bracketed by G-C base
pairs (though the other mismatch is flanked by G-U wobble base pairs). The similarities between
the CUG, CCUG and cTNT stems suggest NIBNLl recognizes both its pathogenic and natural
RNA targets through an analogous mode of recognition. However, the differences between the
RNAs suggest that MBNLl may have complex binding specificity.
Clearly MBNLl can bind a range of RNA stems, but the common theme of pyrimidine-
pyrimidine mismatches and presence of G-C and C-G base pairs indicates these are requirements
for binding by MBNLl. Further studies are necessary to fully define the specificity of MBNLl
before predictions can be made to identify binding sites in other MBNLl regulated pre-mRNAs.
Another challenge is that these potential regulatory stem-loops will not necessarily be predicted
by folding programs due to the lack of consecutive base pairs and presence of mismatches as
observed for the cTNT intron 4 stem-loop.
MBNLl's role as a splicing regulator for the cTNT pre-mRNA
At the beginning of my dissertation work, I hypothesized that a possible mechanism
through which MBNL1 might regulate the exclusion of exon S in the cTNT pre-mRNA is that
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MBNLl could compete for binding ofthe intron with other splicing factors. My initial findings
supported this model, as mutations made to the cTNT splicing minigene showed that recruitment
ofMBNLl to a stem-loop with CUG repeats (instead of the endogenous sequence) also causes
repression of exon 5. The replacement of the endogenous binding site with another sequence that
MBNLl binds causes MBNLl dependent repression of exon 5, while minor mutations that
significantly reduce MBNLl 's binding abolishes MBNLl ability to repress inclusion of exon 5.
These results indicate that direct binding of MBNLl to this stem-loop is required for the
repression of exon 5.
Analysis of the sequences adjacent to MBNLl 's binding site suggested that U2AF65
binding might be affected by MBNLl. I found that MBNLl and U2AF65 do indeed directly
compete for binding and that this competition inhibits U2AF65 from recruiting the U2 snRNP to
the branch-point (Chapter III). The competition ofMBNLl with U2AF65 does not itself
constitute a novel mechanism, as other alternative splicing factors have previously been shown to
compete directly with U2AF65. The alternative splicing factor Sex Lethal (Sxl) has been shown
to compete with U2AF65 in the tra and msl-2 pre-mRNAs (88, 89), while the poly-pyrimidine
Tract Binding Protein (PTB) has been observed to compete with U2AF65 for sequences within
the a- or ~-tropomyosin pre-mRNAs (94, 95). Sxl and PTB both have binding specificities
similar to that of U2AF65, as all three proteins primarily prefer long runs of single-stranded uracil
residues (94). When competitively binding with U2AF65, both Sxl and PTB are considered to
occlude the U2AF65 binding site, and sterically inhibit U2AF65 from accessing its binding site.
On the other hand, MBNLl has a different binding specificity from U2AF65, and binds adjacent
sequences outside of the py-tract. I cannot rule out steric contributions to the competition between
MBNLl and U2AF65, but the fluorescence assay strongly suggests that these proteins bind this
RNA in different conformations (Chapter III, Figure 6). Both the differential binding sites of
MBNLl and U2AF65, and the role that RNA secondary structure can play in modulating
U2AF65 binding, suggest that these splicing factors compete for recognition of the 3' end of
intron 4 largely through binding mutually exclusive RNA structures.
Like other factors regulating splicing, MBNLl functions in one context to exclude an
exon as described for the cTNT exon 5, while for other pre-mRNA the presence ofMBNLl
enhances the inclusion of a particular exon. One general mechanism for MBNLl 's regulation of
alternative splicing could be that the location of MBNLl binding dictates whether it represses or
enhances inclusion of an exon. One simply model would be that MBNLl represses exon
----------------_._-_.--- ----
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inclusion ifit binds upstream of the exon, or enhances exon inclusion ifit binds downstream of
the exon. This has been found for other splicing factors, such as NOVA (82). Supporting this
model for MBNLl, I found that MBNLl represses cTNT exon 5 and bound directly upstream of
the exon 5 (Chapter II and III), and Yuan and colleagues found that MBNLl represses exon F in
the Tnnt3 pre-mRNA and binds directly upstream of that exon as well (74). Furthermore,
MBNLl enhances inclusion of exon 22 of the Sercal pre-mRNA and was found to cross-link
downstream of the exon (85). While there are only three identified binding sites, they are
consistent with the model. More binding sites are required to fully articulate the affect of
MBNLl 's binding site location on its regulatory function.
Beyond the location of the binding, the general mechanisms by which MBNLl either
represses or enhances inclusion of an exon are relatively unclear. When binding upstream of exon
5 in the cTNT pre-mRNA, I found that MBNLl competed with the splicing factor U2AF65 to
repress exon 5 (Chapter II and III). While the mechanism for repression of exon F in the Tnnt3
pre-mRNA is unknown, MBNLl 's binding site is also adjacent to a potential U2AF65 binding
site in that intron (74). This is highly suggestive that MBNLl may repress inclusion of exon F in
that pre-mRNA in a similar mechanism as it does in the cTNT pre-mRNA. As all the protein and
protein-RNA complexes that recognize the 3' end of introns are thought to bind the intron in a
single-stranded fashion, it is possible that MBNLl may repress exon inclusion through a general
mechanism of sequestering important sequences in stem-loops. Further binding sites need to be
articulated and mechanistically studied to see if this is a general mechanism by which MBNLI
represses exons.
Less data is available to propose a mechanism through which MBNLl enhances inclusion
of exons, as only one cross-linking site has been determined in the Sercal pre-mRNA. As
MBNLl can inhibit recognition of U2AF65 by sequestering its binding site in a loop in the cTNT
pre-mRNA, a potential mechanism through which MBNLl could enhance exon inclusion would
be to sequester exonic or intronic splicing silencers in a stem-loop. This would be an elegant
model, in that MBNLl would always regulate splicing by sequestering binding sites of other
splicing regulators. However, MBNLl may have a completely different mechanism for enhancing
exonic inclusion. Another possibility is that MBNLl could recruit other proteins to the 5' splice
site, which was recently shown for the splicing regulator CUG-BP2 (146).
._--_._._---_. --------
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The novel role of MBNLI in regulating alternative splicing by
modulating RNA secondary structure
To our knowledge, the competition between MBNLl and V2AF65 represents the first
example of an alternative splicing factor that regulates splicing primarily through modulation of
an RNA structural element and not through direct occlusion of another splicing factor's binding
site. It is well documented that RNA structural elements alone can regulate alternative splicing.
For instance, stable structures have been shown to inhibit VI snRNP binding to the 5'-splice site
following exon 7 of both the SMN1 and SMN2 pre-mRNAs (96). Other structural elements that
encompass exon 6B in chicken ~-tropomysin have been shown to inhibit binding of all the V
snRNPs, promoting the skipping of that exon (97). At present, it is unclear whether these
examples involve alternative splicing factors that regulate these RNA structures, as MBNLl
appears to regulate secondary structures within the cTNT pre-mRNA.
Other alternative splicing factors have indeed been postulated to regulate RNA structural
elements, but there is no clear evidence to show that these factors actually modulate RNA
structure in a way that directly regulates alternative splicing. For example, the splicing factor
hnRNP Al has been shown to inhibit binding of splicing factors ASF/SF2 and SC35 when they
regulate splicing of the tat pre-mRNA from HIV-I (98). Binding ofhnRNP Al is thought to alter
the secondary structure of the pre-mRNA in a way that affects splicing (99), but this has not been
demonstrated. Similarly, ribosomal protein L32 from S. cerevisiae binds a structured RNA
element near the 5' -splice site of an intron within its own pre-mRNA, leading to intron retention
(l00). However, this structured binding site allows for recruitment of the VI snRNP, showing
that RNA structures do not always inhibit binding of the V snRNPs (l01). It is still unclear how
L32 causes intron retention if it does not inhibit binding ofVI. In regards to the competition
between MBNLl and V2AF65, it has been demonstrated with a crystal structure that V2AF65
binds the py-tract in a single-stranded structure (l02). In this structure, seven uridine residues
bind along two RNA recognition motifs of V2AF65, leaving the 3' and 5' ends spatially far from
each other. This crystal structure sheds light on why V2AF65 must bind the cTNT intron in a
single-stranded form, as it is unlikely that the stem could fonn with the loop in such an extended
structure.
At present, I have shown that MBNLl is the first alternative splicing factor to be
identified that regulates alternative splicing on the level of RNA structure. It is likely that other
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examples will follow as it is becoming increasingly apparent that RNA structure plays important
roles in controlling pre-mRNA splicing.
The small molecule pentamidine as a potential therapeutic for Myotonic
Dystrophy
Many small molecules have been shown to bind and affect nucleic acid structure and
function, which were reviewed in the Discussion of Chapter IV. My results indicate that small
molecules can also be used to target CUG repeats and alleviate MBNLl sequestration. The small
molecule pentamidine shows strong promise as a lead compound as a therapeutic for DM as it
was effective altering MBNLl sequestration in an in vitro assay and three in vivo based assays.
My results suggest pentamidine can, at least, partially target CUG repeats and release MBNLl.
As pentamidine is known to bind B-form DNA in the minor groove (127), it is interesting to note
that Mooers and colleagues previously showed that CUG repeats form an A-form structure,
despite the U-U mismatches (40). Although the minor grooves of A-form and B-form nucleic
acid differ in architecture it is tempting to speculate that pentamidine binds the minor groove of
the A-form CUG repeats.
The results with pentamidine are in contrast to neomycin B which also disrupted the
MBNLl-CUG repeat interaction in vitro (Chapter IV, Figure 1), but did not rescue mis-splicing
of any of the tested targets (Chapter IV, Figure 4). Both pentamidine and neomycin B are known
to bind many different nucleic targets, but only pentamidine displayed the ability to reverse the
mis-splicing of four different pre-mRNAs affected by CUG repeats. These results suggest that
pentamidine has sufficient specificity for CUG repeats to have an effect in these assays,
specificity which neomycin B apparently lacks.
The window of efficacy for pentamidine treatment in the DM1 cell culture and the mouse
model is narrow. Substantial cell death is observed in BeLa cells with pentamidine treatments of
100 to 125 !-!M. Raising the concentration of pentamidine for the mice treatments is also
problematic because pentamidine dosages of 30 mg/kg twice a day are lethal to the mice, while
40 mg/kg twice once a day only partially relieves mis-splicing of the two tested pre-mRNAs
(Chapter IV, Figure 6). To overcome this toxicity, modifications to pentamidine will be
performed to enhance the affinity and specificity of pentamidine for CUG repeats, thus allowing
for a lower dosage treatment. Possible modifications are reviewed in the Discussion of Chapter
IV.
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Previous potential therapeutic approaches for DMI have ranged from over-expression of
MBNLl, RNA interference against the CUG repeats, to targeted degradation ofthe mutant
DMPK transcript with an RNA ribozyme (34-37). We have now demonstrated that releasing
MBNLl from the CUG repeats with a small molecule is another valid approach that should be
considered for treating DMI.
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